0001410939-21-000007 | 10-K | XBRL Viewer

Cover - USD ($) $ in Millions	12 Months Ended
Cover - USD ($) $ in Millions	Dec. 31, 2020	Feb. 28, 2021	Jun. 30, 2020
Document And Entity Information
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36080
Entity Registrant Name	IVERIC bio, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8185347
Entity Address, Address Line One	Five Penn Plaza,
Entity Address, Address Line Two	Suite 2372
Entity Address, City or Town	New York,
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10001
City Area Code	212
Local Phone Number	845-8200
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ISEE
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 442.6
Entity Common Stock, Shares Outstanding (in shares)		90,140,797
Documents Incorporated by Reference	Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant's 2021 Annual Meeting of Shareholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant's fiscal year ended December 31, 2020.
Entity Central Index Key	0001410939
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 66,373	$ 125,699
Available for sale securities	143,674	0
Prepaid expenses and other current assets	4,791	2,043
Income tax receivable	1,765	882
Total current assets	216,603	128,624
Property and equipment, net	26	173
Right-of-use assets, net	120	496
Income tax receivable, non-current	0	882
Other assets	5	12
Total assets	216,754	130,187
Current liabilities
Accrued research and development expenses	12,284	6,860
Accounts payable and accrued expenses	12,792	5,629
Lease liability, current	54	495
Total current liabilities	25,130	12,984
Lease liability, non-current	61	0
Total liabilities	25,191	12,984
Stockholders' equity
Preferred stock—$0.001 par value, 5,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock—0.001 par value, 200,000,000 shares authorized, 90,120,797 and 49,627,064 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	90	50
Additional paid-in capital	756,543	597,679
Accumulated deficit	(565,073)	(480,526)
Accumulated other comprehensive income	3	0
Total stockholders' equity	191,563	117,203
Total liabilities and stockholders' equity	$ 216,754	$ 130,187

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	90,120,797	49,627,064
Common stock, shares outstanding (in shares)	90,120,797	49,627,064

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating expenses:
Research and development	$ 62,784	$ 39,644	$ 41,737
General and administrative	25,952	21,628	23,612
Total operating expenses	88,736	61,272	65,349
Loss from operations	(88,736)	(61,272)	(65,349)
Interest income	500	2,151	2,389
Gain on extinguishment of Royalty Purchase Liability	0	0	125,000
Other income (expense), net	(6)	151	(16)
Income (loss) before income tax benefit	(88,242)	(58,970)	62,024
Income tax benefit	3,695	111	1,063
Net income (loss)	$ (84,547)	$ (58,859)	$ 63,087
Net income (loss) per common share:
Basic (in dollars per share)	$ (1.14)	$ (1.39)	$ 1.70
Dilutive (in dollars per share)	$ (1.14)	$ (1.39)	$ 1.70
Weighted average common shares outstanding:
Basic (in shares)	74,185	42,224	37,061
Dilutive (in shares)	74,185	42,224	37,088

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ (84,547)	$ (58,859)	$ 63,087
Other comprehensive income
Unrealized gain on available for sale securities, net of tax	3	0	0
Other comprehensive income	3	0	0
Comprehensive income (loss)	$ (84,544)	$ (58,859)	$ 63,087

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Underwritten Offering	Private Placement	Junior Series A Preferred Stock	Common Stock	Common Stock Underwritten Offering	Common Stock Private Placement	Additional paid-in capital	Additional paid-in capital Underwritten Offering	Additional paid-in capital Private Placement	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2017				0	36,110
Balance at beginning of period at Dec. 31, 2017	$ 38,041			$ 0	$ 36			$ 522,759			$ (484,754)	$ 0
Increase (Decrease) in Stockholders' Equity
Issuance of common stock related to acquisition (in shares)					5,175
Issuance of common stock related to acquisition	11,694				$ 5			11,689
Issuance of common stock under employee stock compensation plans and warrants (in shares)					112
Issuance of common stock under employee stock compensation plans and warrants	65				$ 0			65
Share-based compensation	11,072							11,072
Net income	63,087										63,087
Unrealized gain on available for sale securities, net of tax	0
Balance at end of period (in shares) at Dec. 31, 2018				0	41,397
Ending balance at Dec. 31, 2018	123,959			$ 0	$ 41			545,585			(421,667)	0
Increase (Decrease) in Stockholders' Equity
Issuance of common stock and pre-funded warrants, net (in shares)					7,750
Issuance of common stock and pre-funded warrants, net	42,565				$ 8			42,557
Issuance of common stock related to acquisition (in shares)					75
Issuance of common stock related to acquisition	85							85
Issuance of common stock under employee stock compensation plans (in shares)					405
Issuance of common stock under employee stock compensation plans	273				$ 1			272
Share-based compensation	9,180							9,180
Net income	(58,859)										(58,859)
Unrealized gain on available for sale securities, net of tax	0
Balance at end of period (in shares) at Dec. 31, 2019				0	49,627
Ending balance at Dec. 31, 2019	117,203			$ 0	$ 50			597,679			(480,526)	0
Increase (Decrease) in Stockholders' Equity
Issuance of common stock and pre-funded warrants, net (in shares)					2,500	28,504	8,649
Issuance of common stock and pre-funded warrants, net	0	$ 116,883	$ 33,237		$ 2	$ 28	$ 9	(2)	$ 116,855	$ 33,228
Issuance of common stock under employee stock compensation plans and warrants (in shares)					841
Issuance of common stock under employee stock compensation plans and warrants	461				$ 1			460
Share-based compensation	8,323							8,323
Net income	(84,547)										(84,547)
Unrealized gain on available for sale securities, net of tax	3											3
Balance at end of period (in shares) at Dec. 31, 2020				0	90,121
Ending balance at Dec. 31, 2020	$ 191,563			$ 0	$ 90			$ 756,543			$ (565,073)	$ 3

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Activities
Net income (loss)	$ (84,547)	$ (58,859)	$ 63,087
Adjustments to reconcile net loss to net cash (used in) provided by operating activities
Depreciation	143	162	183
Amortization of premium and discounts on investment securities	462	0	0
Non-cash charge on acquired in-process research and development	0	0	5,619
Gain on sale of property and equipment	0	(150)	0
Non-cash gain on extinguishment of royalty purchase agreement	0	0	(125,000)
Share-based compensation	8,323	9,180	11,072
Stock-based consideration in connection with license acquisition	0	85	0
Changes in operating assets and liabilities:
Income tax receivable	0	1,765	1,387
Prepaid expense and other assets	(2,742)	45	1,070
Accrued interest receivable	(323)	0	0
Accrued research and development expenses	5,424	(477)	2,353
Accounts payable and accrued expenses	7,163	(241)	(1,682)
Net cash used in operating activities	(66,097)	(48,490)	(41,911)
Investing Activities
Purchase of marketable securities	(143,810)	0	0
Proceeds from sale of assets	0	150	0
Net cash provided by (used in) investing activities	(143,810)	150	0
Financing Activities
Proceeds from employee stock plan purchases and stock option exercises	461	273	65
Net cash provided by financing activities	150,581	42,838	6,140
Net change in cash and cash equivalents	(59,326)	(5,502)	(35,771)
Cash and cash equivalents
Beginning of period	125,699	131,201	166,972
End of period	66,373	125,699	131,201
End of period
Interest	(3,327)	(1,893)	(2,467)
Income taxes received, net
Supplemental disclosures of non-cash information related to investing activities	3	0	0
Common stock issued to acquire net assets of Inception 4, Inc.	0	0	11,694
Operating right-of-use assets obtained in exchange for lease obligations	166	1,469
Public Stock Offering
Financing Activities
Proceeds from issuance of common stock and pre-funded warrants, net, and related to acquisition	116,883	42,565	0
Private Placement
Financing Activities
Proceeds from issuance of common stock and pre-funded warrants, net, and related to acquisition	33,237	0	0
Inception 4
Financing Activities
Proceeds from issuance of common stock and pre-funded warrants, net, and related to acquisition	$ 0	$ 0	$ 6,075

Business	12 Months Ended
Business	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	Business Description of Business and Organization IVERIC bio, Inc. (the “Company” or “IVERIC”) is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases ("IRDs"). The Company believes that both therapeutics and gene therapy serve important roles in drug development and providing potential treatment options for patients suffering from retinal diseases. The Company's therapeutics portfolio consists of Zimura® (avacincaptad pegol), a complement C5 inhibitor, and its preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein ("HtrA1") inhibitor. The Company is targeting the following diseases with Zimura: •Geographic Atrophy ("GA"), which is the advanced stage of age-related macular degeneration ("AMD"), and is characterized by marked thinning or atrophy of retinal tissue, leading to irreversible loss of vision; and •autosomal recessive Stargardt disease ("STGD1"), which is an orphan inherited condition characterized by progressive damage to the central portion of the retina (the "macula") and other retinal tissue, leading to loss of vision. The Company previously also evaluated Zimura in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor ("anti-VEGF") agent, for the treatment of wet AMD, for which the Company completed a Phase 2a clinical trial during the fourth quarter of 2018. The Company is developing IC-500 for GA secondary to AMD and potentially other age-related retinal diseases. The Company's gene therapy portfolio consists of two product candidates in preclinical development (IC-100 and IC-200) and several ongoing research and development programs, each of which uses adeno-associated virus ("AAV") for gene delivery. These AAV mediated gene therapy programs are targeting the following orphan IRDs: •rhodopsin-mediated autosomal dominant retinitis pigmentosa ("RHO-adRP"), which is characterized by progressive and severe bilateral loss of vision leading to blindness; •IRDs associated with mutations in the BEST1 gene, including Best vitelliform macular dystrophy ("Best disease"), which is generally characterized by bilateral egg yolk-like lesions in the macula, which, over time, progress to atrophy and loss of vision; •Leber Congenital Amaurosis type 10 ("LCA10"), which is characterized by severe bilateral loss of vision at or soon after birth; •autosomal recessive Stargardt disease; and •IRDs associated with mutations in the USH2A gene, which include Usher syndrome type 2A and USH2A-associated nonsyndromatic autosomal recessive retinitis pigmentosa. The Company is developing IC-100 for RHO-adRP and IC-200 for BEST1-related IRDs.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include all adjustments necessary for the fair presentation of

the Company's financial position for the periods presented. The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Segment and geographic information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.

Use of Estimates

The preparation of financial statements and related disclosures in conformity with GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company's Consolidated Balance Sheets and the amount of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for research and development costs, accounting for share-based compensation and accounting for income taxes. Actual results could differ from those estimates.

Cash, Cash Equivalents and Available for Sale Securities

The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. The carrying amounts reported in the Balance Sheets for cash and cash equivalents are valued at cost, which approximates their fair value.

The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Available for sale securities with original maturities of greater than one year are recorded as non-current assets. Available for sale securities are recorded at fair value and unrealized gains and losses are recorded within other comprehensive income.

On a quarterly basis, the Company reviews the status of each security in an unrealized loss position, to evaluate the existence of potential credit losses. The Company first considers whether it intends to sell, or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through income. For securities that do not meet this criteria, the Company considers a number of factors to determine if the decline in fair value has resulted from credit losses or other factors, including but not limited to: (1) the extent of the decline; (2) changes to the rating of the security by a rating agency; (3) any adverse conditions specific to the security; and (4) other market conditions that may affect the fair value of the security. If this assessment indicates that a credit loss exists and the present value of cash flows expected to be collected is less than the amortized cost basis, an allowance for credit losses is required for the credit loss. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income.

As of December 31, 2020, the Company had cash, cash equivalents and available for sale securities of approximately $210.0 million. The Company believes that its cash, cash equivalents and available for sale securities as of December 31, 2020 will be sufficient to fund its operations and capital expenditure requirements as currently planned for at least the next 12 months from the filing of the Company's Annual Report on Form 10-K.

Concentration of Credit Risk

The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents and available for sale securities. The Company maintains its cash in bank accounts, the balance of which generally exceed federally insured limits. The Company maintains its cash equivalents and available for sale securities in investments in money market funds, in U.S. Treasury securities and asset-backed securities and investment-grade corporate debt securities with original maturities of 90 days or less.

The Company believes it is not exposed to significant credit risk on its cash and cash equivalents.

Concentration of Suppliers

The Company historically relied upon a single third-party manufacturer to provide the drug substance for Zimura on a purchase order basis. The Company also historically relied upon a single third-party manufacturer to provide fill/finish services for clinical supplies of Zimura. The Company has engaged one additional third-party manufacturer to provide drug substance for Zimura and one additional third-party manufacturer to provide fill/finish services for clinical supplies of Zimura. In addition, the Company currently relies upon a single third-party supplier to supply on a purchase order basis the polyethylene glycol starting material used to manufacture Zimura. Furthermore, the Company and its contract manufacturers currently rely upon sole-source suppliers of certain raw materials and other specialized components of production used in the manufacture and fill/finish of Zimura. The Company currently relies exclusively upon a single third-party contract manufacturer for IC-100 and IC-200, and also relies on sole-source suppliers for certain starting materials used in the manufacture of such product candidates. The Company currently relies upon a single third-party contract manufacturer to conduct process development, scale-up and GMP manufacture of the drug substance for IC-500 for preclinical toxicology studies and early-stage clinical trials and a single third-party contract manufacturer to conduct formulation development activities for IC-500. If the Company’s third-party manufacturers or fill/finish service providers should become unavailable to the Company for any reason, including as a result of capacity constraints, different business objectives, financial difficulties, insolvency or the COVID-19 pandemic, the Company believes that there are a limited number of potential replacement manufacturers, and the Company likely would incur added costs and delays in identifying or qualifying such replacements.

Foreign Currency Translation

The Company considers the U.S. dollar to be its functional currency. Expenses denominated in foreign currencies are translated at the exchange rate on the date the expense is incurred. The effect of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars is included in the Consolidated Statements of Operations and Comprehensive Loss. Foreign exchange transaction gains and losses are included in the results of operations and are not material in the Company's financial statements.

Financial Instruments

Cash equivalents are reflected in the accompanying financial statements at fair value. The carrying amount of accounts payable and accrued expenses, including accrued research and development expenses, approximates fair value due to the short-term nature of those instruments.

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The Company reviews investments on a periodic basis for other than temporary impairments. This review is subjective as it requires management to evaluate whether an event or change in circumstances has occurred in the period that may have a significant adverse effect on the fair value of the investment. The Company uses the market approach to measure fair value for its financial assets. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets. The Company classifies its corporate debt securities within the fair value hierarchy as Level 2 assets, as it primarily utilizes quoted market prices or rates for similar instruments to value these securities.

Leases

The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, it recognizes a right-to-use ("ROU") lease asset and operating lease liability on the Company's Consolidated Balance Sheet. ROU lease assets represent the Company's right to use the underlying asset for the lease term and the lease obligation represents the Company's commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit discount rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset includes any lease payments made prior to commencement and excludes any lease incentives.

The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. For all office lease agreements the Company combines lease and nonlease components. Leases with an initial term of 12 months or less are not recorded on the Company's Consolidated Balance Sheet.

Property and Equipment

Property and equipment, which consists mainly of clinical equipment, computers, software, other office equipment, and leasehold improvements, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset.

Research and Development

The Company's research and development expenses primarily consist of costs associated with the manufacturing, development, and preclinical and clinical testing of the Company's product candidates and costs associated with its collaborative gene therapy sponsored research programs. The Company's research and development expenses consist of:

•external research and development expenses incurred under arrangements with third parties, such as academic research collaborators, contract research organizations ("CROs") and contract development and manufacturing organizations ("CDMOs") and other vendors for the production and analysis of drug substance and drug product; and

•employee-related expenses for employees dedicated to research and development activities, including salaries, benefits and share-based compensation expense.

Research and development expenses also include costs of acquired product licenses, in-process research and development, and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to collaborators.

All research and development expenses are charged to operations as incurred in accordance with ASC 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.

Income Taxes

The Company utilizes the liability method of accounting for deferred income taxes, as set forth in ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company's policy is to record interest and penalties on uncertain tax positions as income tax expense.

Share-Based Compensation

The Company follows the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee directors and consultants, including employee stock options, restricted stock units (“RSUs”) and options granted to employees to purchase shares under the 2016 Employee Stock Purchase Plan (the “ESPP”). Share-based compensation expense is based on the grant date fair value estimated in accordance with the provisions of ASC 718 and is generally recognized as an expense over the requisite service period, net of estimated forfeitures. For grants containing performance-based vesting provisions, expense is recognized over the estimated achievement period only when the performance-based milestone is deemed probable of achievement. If performance-based milestones are later determined not to be probable of achievement,

then all previously recorded stock-based compensation expense associated with such options will be reversed during the period in which the Company makes this determination.

The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from its estimates. The Company uses historical data to estimate pre-vesting forfeitures and record share-based compensation expense only for those awards that are expected to vest. To the extent that actual forfeitures differ from the Company's estimates, the difference is recorded as a cumulative adjustment in the period the estimates were revised.

Stock Options

The Company estimates the fair value of stock options granted to employees, non-employees and non-employee directors on the date of grant using the Black-Scholes option-pricing model. The Company's computation of stock-price volatility is based on daily historical volatility during the time period that corresponds to the expected option term. The Company's computation of expected term is determined using the expected term of stock option grants to employees based on an analysis of actual option exercises. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends to stockholders and has no current intentions to pay cash dividends. The risk-free interest rate is based on the zero-coupon U.S. Treasury yield at the date of grant for a term equivalent to the expected term of the option.

The weighted-average assumptions used to estimate grant date fair value of stock options using the Black-Scholes option pricing model were as follows for the years ended December 31, 2020, 2019 and 2018:


	Years ended December 31,
	2020	2019	2018
Expected common stock price volatility	118%	110%	85%
Risk-free interest rate	0.22%-1.34%	1.38%-2.54%	2.39%-2.95%
Expected term of options (years)	4.6	4.8	6.0
Expected dividend yield	—	—	—

RSUs

The Company estimates the fair value of RSUs granted to employees using the closing market price of the Company's common stock on the date of grant.

ESPP

In April 2016, the Company's board of directors adopted the ESPP pursuant to which the Company may sell up to an aggregate of 1,000,000 shares of its common stock. The ESPP was approved by the Company’s stockholders in June 2016. The ESPP is considered compensatory and the fair value of the discount and look back provision are estimated using the Black-Scholes option-pricing model and recognized over the six month withholding period prior to purchase.

Share-based compensation expense includes expenses related to stock options and RSUs granted to employees, non-employee directors and consultants, as well as the option granted to employees to purchase shares under the ESPP, all of which have been reported in the Company’s Statements of Operations as follows:


	Years ended December 31,
	2020		2019		2018
Research and development	$	4,166	$	4,260	$	4,967
General and administrative	4,157		4,920		6,105
Total	$	8,323	$	9,180	$	11,072

Recently Adopted Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standard Update ("ASU") 2016-13 Financial Instruments (Topic 326) Measurement of Credit Losses on Financial Instrument (“CECL”). ASU 2016-13 requires an allowance for expected credit losses on financial assets be recognized as early as day one of the instrument. This ASU departs from the incurred loss model which means the probability threshold is removed. It considers more forward-looking information and requires the entity to estimate its credit losses as far as it can reasonably estimate. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard effective January 1, 2020 with no material impact to its financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, including, among other changes, the consideration of costs and benefits when evaluating disclosure requirements. For public companies, the amendments became effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual periods. The Company adopted this accounting standard effective January 1, 2020 with no material impact to its financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance became effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. The Company adopted this accounting standard effective January 1, 2020 with no material impact to its financial statements.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808), which clarifies the interaction between the guidance for collaborative arrangements (Topic 808) and the new revenue recognition standard (Topic 606). For public companies, the amendments became effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual periods. The Company adopted this accounting standard effective January 1, 2020 with no material impact to its financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company adopted this accounting standard effective January 1, 2020 with no material impact to its financial statements.

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2020
Equity [Abstract]
Common Stock	Common Stock June 2020 Public Offering and Private Placement In June 2020, the Company closed an underwritten public offering in which it sold 28,503,220 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase additional shares of its common stock, at a price to the public of $4.10 per share, and at a price to the underwriters of $3.854 per share. The Company also sold to certain investors in lieu of common stock, pre-funded warrants to purchase 1,914,280 shares of its common stock at a price to the public of $4.099 per share underlying each pre-funded warrant, and at a price to the underwriters of $3.853 per share underlying each pre-funded warrant. The pre-funded warrants are immediately exercisable with certain restrictions and do not expire. Concurrently with the June 2020 public offering, the Company completed a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), in which it sold 8,649,453 shares of its common stock to affiliates of Vivo Capital, LLC and Samsara BioCapital, LP (the "Private Placement Purchasers"), at a purchase price equal to $4.10 per share, which is the price to the public in the public offering. The shares in the private placement were issued pursuant to a stock purchase agreement entered into among the Company and the Private Placement Purchasers. The net proceeds from the public offering and private placement, after deducting underwriting discounts, placement agent fees and other offering expenses of approximately $10.1 million, was approximately $150.1 million. December 2019 Public Offering On December 6, 2019, the Company completed an underwritten public offering in which it sold 6,250,000 shares of its common stock at a public offering price of $4.00 per share, and it sold to certain investors pre-funded warrants to purchase 3,750,000 shares of its common stock at a public offering price of $3.999 per share underlying each warrant. The offering included an option for the underwriters to purchase up to an additional 1,500,000 shares of its common stock, which was subsequently exercised in full by the underwriters. The shares of its common stock were sold to the underwriters at a purchase price of $3.736 per share and the pre-funded warrants were sold to the underwriters at a purchase price of $3.735 per share underlying each warrant. The pre-funded warrants are immediately exercisable with certain restrictions and do not expire. The net proceeds from the offering, after deducting underwriting discounts and commissions of $3.0 million and other offering expenses of $0.4 million, was approximately $42.6 million. The Company evaluated the pre-funded warrants for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and ASC 815-40, Derivatives and Hedging. Based on the provisions governing the pre-funded warrants in the applicable agreement, the Company determined that the pre-funded warrants meet the criteria required to be classified as an equity award subject to the guidance in ASC 815-10 and 815-40 and should effectively be treated as outstanding common shares in both basic and diluted EPS calculations. miniCEP290 Program - University of Massachusetts On July 22, 2019, the Company entered into its exclusive license agreement with the University of Massachusetts ("UMass") for rights to its miniCEP290 program (the "miniCEP290 License Agreement"). Pursuant to the terms of the miniCEP290 License Agreement, the Company issued to UMass 75,000 shares of the Company's common stock, which were valued at approximately $0.1 million. Based on and relying on certain representations made by UMass, the Company issued those shares pursuant to an exemption from registration afforded by Section 4(a)(2) of the Securities Act.

Net Income (Loss) Per Common Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Net Income (Loss) Per Common Share

Net Income (Loss) Per Common ShareBasic and diluted net loss per common share is determined by dividing net loss by the weighted average common shares and pre-funded warrants outstanding during the period. Basic and diluted shares outstanding includes the weighted average effect of the Company's outstanding pre-funded warrants as the exercise of such pre-funded warrants requires nominal consideration to be given for the delivery of the corresponding shares of common stock. As of December 31, 2020 and 2019, the Company had 3,164,280 and 3,750,000 pre-funded warrants outstanding, respectively, which if exercised, would increase the number of shares of common stock issued and outstanding. For the periods when there is a net loss, shares underlying stock options and RSUs have been excluded from the calculation of diluted net loss per common share because the effect of including such shares would be anti-dilutive. Therefore, the weighted average common shares used to calculate both basic and diluted net loss per common share would be the same.

The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods indicated:


	Years ended December 31,
	2020		2019		2018
Basic and diluted net income (loss) per common share calculation:
Net income (loss)	$	(84,547)	$	(58,859)	$	63,087
Weighted average common shares outstanding - basic	74,185		42,224		37,061
Plus: net effect of dilutive stock options and unvested restricted stock units	—		—		27
Weighted average common shares outstanding - dilutive	74,185		42,224		37,088
Net income (loss) per common share - basic	$	(1.14)	$	(1.39)	$	1.70
Net income (loss) per common share - diluted	$	(1.14)	$	(1.39)	$	1.70

The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding for the periods presented, as the effect of including such shares would be anti-dilutive:


	Years ended December 31,
	2020	2019	2018
Stock options outstanding	8,928	6,780	5,873
Restricted stock units	1,958	1,481	601
Total	10,886	8,261	6,474

Cash, Cash Equivalents and Available for Sale Securities

12 Months Ended

Dec. 31, 2020

Cash and Cash Equivalents [Abstract]

Cash, Cash Equivalents and Available for Sale Securities

The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of purchase to be cash equivalents. As of December 31, 2020 and December 31, 2019 the Company had cash and cash equivalents of approximately $66.4 million and $125.7 million, respectively. Cash and cash equivalents at December 31, 2020 and December 31, 2019 included cash of $8.4 million and $3.2 million, respectively. As of December 31, 2020 and December 31, 2019, cash and cash equivalents also included $58.0 million and $122.5 million, respectively, of investments in money market funds and certain short-term investment-grade corporate debt securities with original maturities of 90 days or less.

The Company considers securities with original maturities of greater than 90 days at the date of purchase to be available for sale securities. The Company had available for sale securities of approximately $143.7 million at December 31, 2020. The available for sale securities listed at December 31, 2020 mature in one year or less. The Company held no available for sale securities at December 31, 2019.

The Company evaluates securities with unrealized losses, if any, to determine whether the decline in fair value has resulted from credit loss or other factors. The Company has determined that there were no credit losses in fair value of its investments as of December 31, 2020. Factors considered in determining whether a loss resulted from a credit loss or other factors included the length of time and extent to which the investment’s fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, the extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not the Company will be required to sell the security before the recovery of its amortized cost.

The Company classifies these securities as available for sale. However, the Company has not sold and does not currently intend to sell its investments and the Company believes it is more likely than not that the Company will recover the carrying value of these investments.

Available for sale securities, including carrying value and estimated fair values, are summarized as follows:


	As of December 31, 2020
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
U.S. Treasury securities	$	54,225	$	8	$	—	$	54,233
Corporate debt securities	79,282		4		(10)		79,276
Asset-backed securities	10,164		1		—		10,165
Total	$	143,671	$	13	$	(10)	$	143,674

The Company's available for sale securities are reported at fair value on the Company's balance sheet. Unrealized gains (losses) are reported within accumulated other comprehensive loss in the statements of comprehensive income (loss). The cost of securities sold and any realized gains/losses from the sale of available for sale securities are based on the specific identification method. The changes in accumulated other comprehensive income (loss) associated with the unrealized loss on available for sale securities for the years ended December 31, 2020 and December 31, 2019 were as follows:


	Years ended December 31,
	2020		2019
Beginning balance	$	—	$	—
Current period changes in fair value before reclassifications, net of tax	3		—
Amounts reclassified from accumulated other comprehensive income, net of tax	—		—
Total other comprehensive income	$	3	$	—
Ending balance	$	3	$	—

Fair Value Measurements

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

The Company reviews investments on a periodic basis for other than temporary impairments. This review is subjective as it requires management to evaluate whether an event or change in circumstances has occurred in the period that may have a significant adverse effect on the fair value of the investment. The Company uses the market approach to measure fair value for its financial assets. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets. The Company classifies its investment-grade corporate debt securities within the fair value hierarchy as Level 2 assets, as it primarily utilizes quoted market prices or rates for similar instruments to value these securities.

The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:

•Level 1—inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market. The Company's Level 1 assets consist of investments in money market funds and U.S. Treasury securities.

•Level 2—inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability. The Company's Level 2 assets may consist of investments in investment-grade corporate debt securities.

•Level 3—inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. The Company does not hold any assets that are measured using Level 3 inputs.

The Company classifies its corporate debt securities within the fair value hierarchy as Level 2 assets, as it primarily utilizes quoted market prices or rates for similar instruments to value these securities.

The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company's assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020:


	Fair Value Measurement Using
	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Investments in money market funds*	$	58,042	$	—	$	—

Investments in U.S. Treasury securities	$	54,233	$	—	$	—
Investments in corporate debt securities*	$	—	$	79,275	$	—
Investments in asset-backed securities	$	—	$	10,166	$	—


	Fair Value Measurement Using
	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Investments in money market funds*	$	108,585	$	—	$	—
Investments in corporate debt securities*	$	—	$	13,875	$	—

*Investments in money market funds and corporate debt securities with maturities less than 90 days are reflected in cash and cash equivalents in the accompanying Balance Sheets.

No transfer of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the years ended December 31, 2020 or December 31, 2019.

Inception 4 Acquisition	12 Months Ended
Inception 4 Acquisition	Dec. 31, 2020
Asset Acquisition [Abstract]
Inception 4 Acquisition	Inception 4 Acquisition In October 2018, the Company entered into an Agreement and Plan of Merger (the “Inception 4 Merger Agreement”) by and among the Company, Orion Ophthalmology Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Company (“Merger Sub I”), Orion Ophthalmology LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of the Company (“Orion”), Inception 4, Inc., a Delaware corporation ("Inception 4"), and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Inception 4, Fortis Advisors LLC, a Delaware limited liability company. Pursuant to the Inception 4 Merger Agreement, in October 2018, the Company acquired Inception 4 through the merger of Merger Sub I with and into Inception 4, with Inception 4 surviving as a direct, wholly owned subsidiary of the Company, and as part of the same overall transaction, the merger of Inception 4 with and into Orion, with Orion surviving as a direct, wholly owned subsidiary of the Company (the transactions are collectively referred to as the "Inception 4 Merger"). Prior to the Inception 4 Merger, Inception 4 was a privately held biotechnology company focused on the research and development of small molecule HtrA1 inhibitors for age-related retinal diseases in humans. Pursuant to the terms of the Inception 4 Merger Agreement, as upfront consideration, the Company issued approximately 5.2 million shares of the Company’s common stock to the former equityholders of Inception 4, which were valued at approximately $11.7 million based on the closing price of the Company’s common stock on the acquisition date equal to $2.26 per share. Additionally, subject to the terms and conditions of the Inception 4 Merger Agreement, the former equityholders of Inception 4 will be entitled to receive contingent payments up to an aggregate of $105.0 million from the Company for the achievement of specified clinical and regulatory milestones, with $45 million of such potential payments relating to GA and $60 million of such potential payments relating to wet AMD. The future milestone payments will be payable in the form of shares of the Company's common stock, calculated based on the price of its common stock over a five-trading day period preceding the achievement of the relevant milestone, unless and until the issuance of such shares would, together with all other shares issued in connection with the Inception 4 Merger, exceed an overall maximum limit of approximately 7.2 million shares, which is equal to 19.9% of the number of issued and outstanding shares of the Company's common stock as of the close of business on the business day prior to the closing date of the Inception 4 Merger, and will be payable in cash thereafter. At closing, the Company acquired all of Inception 4's assets, which included intellectual property and in-process research and development (“IPR&D”) associated with Inception 4’s HtrA1 inhibitor program and approximately $6.1 million in cash. There were no other tangible assets, leases or liabilities. The Company evaluated the acquisition of Inception 4 under ASU No. 2017-01, Business Combinations: Clarifying the Definition of a Business. Based on the results of the analysis performed, the Company concluded that substantially all of the fair value of the gross assets acquired under the Inception 4 Merger Agreement is concentrated in a single identifiable asset. As a result, the Company concluded that the acquisition of Inception 4 does not represent an acquisition of a business and does not qualify as a business combination to be accounted for under ASC 805. Further, the Company concluded that the legal entity is not a variable interest entity under ASC 810 - Consolidation. Consequently, the Company concluded that the acquisition of Inception 4 should be accounted for as an asset acquisition under ASC 805-50. As the contingent consideration is not a derivative under ASC 815 - Derivatives and Hedging, any contingent payments will be recognized when earned or achieved and such amounts will be expensed upon payment for pre-commercial activities and capitalized for regulatory approvals and post-commercial activities. Further, as the acquired IPR&D has no alternative future use, in accordance with ASC 730, at closing, the Company charged to expense its allocated fair value of $6.9 million, which is the total acquisition consideration including transaction costs of $1.3 million less the cash acquired.

Licensing and Commercialization Agreement	12 Months Ended
Licensing and Commercialization Agreement	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Licensing and Commercialization Agreement	Licensing and Commercialization Agreements Zimura License Agreement with Archemix Corp. In September 2011, the Company entered into an amended and restated exclusive license agreement with Archemix Corp. ("Archemix") relating to anti-C5 aptamers (as amended, the "C5 License Agreement"). The C5 License Agreement superseded a July 2007 agreement between the Company and Archemix. Under the C5 License Agreement, the Company holds exclusive worldwide licenses, subject to certain pre–existing rights, under specified patents and technology owned or controlled by Archemix to develop, make, use, sell, offer for sale, distribute for sale, import and export pharmaceutical products comprised of or derived from an anti-C5 aptamer, including Zimura, for the prevention, treatment, cure or control of human indications, diseases, disorders or conditions of the eye, adnexa of the eye, orbit and optic nerve, other than certain expressly excluded applications. In connection with the C5 License Agreement, the Company paid Archemix an upfront licensing fee of $1.0 million and issued to Archemix an aggregate of 2,000,000 shares of its series A-1 preferred stock and 500,000 shares of its series B-1 preferred stock. The Company has paid Archemix an aggregate of $9.0 million in fees based on its achievement of specified clinical milestone events under the C5 License Agreement, including two milestone payments of $1.0 million and $6.0 million, respectively, triggered by the positive 12-month data from, and by completion of, the GATHER1 trial, which the Company paid in March 2020 and October 2020, respectively. Under the C5 License Agreement, for each anti-C5 aptamer product that the Company may develop under the agreement, including Zimura, it is obligated to make additional payments to Archemix of up to an aggregate of $50.5 million if it achieves specified development, clinical and regulatory milestones, with $24.5 million of such payments relating to a first indication, $23.5 million of such payments relating to second and third indications and $2.5 million of such payments relating to sustained delivery applications. Under the C5 License Agreement, it is also obligated to make additional payments to Archemix of up to an aggregate of $22.5 million if it achieves specified commercial milestones based on net product sales of all anti-C5 products licensed under the agreement. It is also obligated to pay Archemix a double-digit percentage of specified non-royalty payments it may receive from any sublicensee of its rights under the C5 License Agreement. The Company is not obligated to pay Archemix a running royalty based on net product sales in connection with the C5 License Agreement. Unless earlier terminated, the C5 License Agreement will expire upon the latest of 12 years after the first commercial sale in any country of the last licensed product, the expiration of the last-to-expire valid claim of the licensed patents that covers a licensed product, and the date on which no further payments of sublicensing income are to be received by the Company. Either the Company or Archemix may terminate the C5 License Agreement if the other party materially breaches the agreement and the breach remains uncured for a specified period. Archemix may also terminate the C5 License Agreement, or may convert the Company's exclusive license under the agreement to a non-exclusive license, if the Company challenges or assists a third party in challenging the validity or enforceability of any of the patents licensed under the agreement. The Company may terminate the agreement at any time and for any or no reason effective at the end of a specified period following its written notice of termination to Archemix. IC-100 Agreements with the University of Florida Research Foundation and the University of Pennsylvania In June 2018, the Company entered into an exclusive global license agreement (the "RHO-adRP License Agreement") with the University of Florida Research Foundation, Incorporated ("UFRF") and the University of Pennsylvania ("Penn" and collectively with UFRF, the "Licensors"). Under the agreement, the Licensors granted the Company a worldwide, exclusive license under specified patent rights and a worldwide, non-exclusive license under specified know-how, including specified preclinical data, to manufacture, develop and commercialize certain AAV gene therapy products for the treatment of rhodopsin-mediated diseases. The rights granted under the RHO-adRP License Agreement included certain patent rights covering IC-100, the Company's novel AAV gene therapy product candidate intended to treat RHO-adRP. In June 2018, the Company paid UFRF, on behalf of both Licensors, a $0.5 million upfront license issuance fee in connection with entry into the agreement, which was recorded as a research and development expense, as well as accrued patent prosecution expenses of approximately $30 thousand, which was recorded as a general and administrative expense. Under the agreement, the Company agreed to pay an annual license maintenance fee in the low double-digit thousands of dollars, which will be payable on an annual basis until the first commercial sale of a licensed product. In addition, the Company agreed to reimburse UFRF for the costs and expenses of patent prosecution and maintenance related to the licensed patent rights. The Company further agreed to pay UFRF, on behalf of both Licensors, up to an aggregate of $23.5 million if the Company achieves specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product and additionally, up to an aggregate of $70.0 million if the Company achieves specified commercial sales milestones with respect to a licensed product. The Company is also obligated to pay UFRF, on behalf of both Licensors, royalties at a low single-digit percentage of net sales of licensed products. Such royalties are subject to customary reductions for lack of patent coverage and loss of regulatory exclusivity. In addition, such royalties with respect to any licensed product in any country may be offset by a specified portion of any royalty payments actually paid by the Company in such country under third-party licenses for patent rights or other intellectual property rights that are necessary to manufacture, develop and commercialize the licensed product in such country. The Company's obligation to pay royalties under the RHO-adRP License Agreement will continue on a licensed product-by-licensed product and country-by-country basis until the latest of: •the expiration of the last-to-expire licensed patent rights covering a licensed product in the country of sale; •the expiration of regulatory exclusivity covering a licensed product in the country of sale; and •ten years from the first commercial sale of the applicable licensed product in the country of sale. Beginning on the earlier of (i) the calendar year following the first commercial sale of a licensed product and (ii) the first business day of 2031, the Company is also obligated to pay certain minimum royalties, not to exceed an amount in the low hundreds of thousands of dollars on an annual basis, which minimum royalties are creditable against the Company's royalty obligation with respect to net sales of licensed products due for the year in which the minimum royalty is paid. In addition, if the Company or an affiliate sublicenses any of the licensed patent rights to a third party, the Company will be obligated to pay UFRF, on behalf of both Licensors, a low double-digit percentage of the consideration received in exchange for such sublicense. If the Company receives a rare pediatric disease priority review voucher from the FDA in connection with obtaining marketing approval for a licensed product and the Company subsequently uses such priority review voucher in connection with a different product candidate, the Company will be obligated to pay UFRF, on behalf of both Licensors, aggregate payments in the low double-digit millions of dollars based on certain marketing approval and commercial sales milestones with respect to such other product candidate. If the Company sells such priority review voucher to a third party, it will be obligated to pay UFRF, on behalf of both licensors, a low double-digit percentage of any consideration received from such third party in connection with such sale. Unless earlier terminated by the Company, the RHO-adRP License Agreement will expire upon the expiration of the Company’s obligation to pay royalties to UFRF on net sales of licensed products. The Company may terminate the agreement at any time for any reason upon prior written notice to UFRF. Penn or UFRF may terminate the RHO-adRP License Agreement in the event of certain breaches by the Company or in the event of certain insolvency events regarding the Company. In addition to the exclusive license agreement, the Company and Penn also entered into to a Master-Sponsored Research Agreement (the "RHO-adRP MSRA"), facilitated by the Penn Center for Innovation. Under the RHO-adRP MSRA, the Company and Penn conducted several preclinical studies of IC-100, as well as a natural history study of RHO-adRP patients. The total amount of funding for the sponsored research covered by statements of work under the RHO-adRP MSRA that the Company has committed to date and is expecting to commit to is in the low single-digit millions of dollars. IC-200 Agreements with University of Pennsylvania and University of Florida Research Foundation In April 2019, the Company entered into an exclusive global license agreement (the "BEST1 License Agreement") with Penn and UFRF. The Company entered into the BEST1 License Agreement by exercising its exclusive option rights under an option agreement that it previously entered into with Penn and UFRF in October 2018. Under the BEST1 License Agreement, Penn and UFRF granted the Company a worldwide, exclusive license under specified patent rights and specified know-how and a worldwide, non-exclusive license under other specified know-how to research, develop, manufacture and commercialize certain AAV gene therapy products, including IC-200, for the treatment of Best disease and other BEST1-related IRDs. In May 2019, the Company paid Penn, for the benefit of the Licensors, a $0.2 million upfront license issuance fee, which was recorded as a research and development expense, and the Company paid UFRF accrued patent prosecution expenses of approximately $18 thousand, which was recorded as a general and administrative expense. The Company has also agreed to pay Penn, for the benefit of the Licensors, an annual license maintenance fee in the low double-digit thousands of dollars, which will be payable on an annual basis until the first commercial sale of a licensed product. In addition, the Company have agreed to pay Penn, for the benefit of the Licensors, a one-time patent grant fee in the low triple-digit thousands of dollars, upon the issuance of a U.S. patent that claims inventions disclosed in the licensed patent rights or know-how or inventions generated under certain related sponsored research agreements with Penn or UFRF, and that is exclusively licensed to the Company. Furthermore, it has agreed to reimburse Penn and UFRF for the costs and expenses of patent prosecution and maintenance related to the licensed patent rights. The Company has further agreed to pay Penn, for the benefit of the Licensors, up to an aggregate of $15.7 million if it achieves specified clinical, marketing approval and reimbursement approval milestones with respect to one licensed product, and up to an aggregate of an additional $3.1 million if it achieves these same milestones with respect to a different licensed product. In addition, it has agreed to pay Penn, for the benefit of the Licensors, up to an aggregate of $48.0 million if it achieves specified commercial sales milestones with respect to one licensed product, and up to an aggregate of an additional $9.6 million if it achieves these same milestones with respect to a different licensed product. The Company is also obligated to pay Penn, for the benefit of the Licensors, royalties at a low single-digit percentage of net sales of licensed products. Such royalties are subject to customary deductions, credits, and reductions for lack of patent coverage and loss of regulatory exclusivity. In addition, such royalties with respect to any licensed product in any country may be offset by a specified portion of any royalty payments actually paid by the Company in such country under third-party licenses to patent rights or other intellectual property rights that are necessary to research, develop, manufacture and commercialize the licensed product in such country. Its obligation to pay royalties under the BEST1 License Agreement will continue on a licensed product-by-licensed product and country-by-country basis until the latest of: •the expiration of the last-to-expire licensed patent rights covering the sale of the applicable licensed product in the country of sale; •the expiration of regulatory exclusivity covering the applicable licensed product in the country of sale; and •10 years from the first commercial sale of the applicable licensed product in the country of sale. Beginning on the earlier of the calendar year following the first commercial sale of a licensed product and calendar year 2032, the Company is also obligated to pay certain minimum royalties, not to exceed an amount in the mid tens of thousands of dollars on an annual basis, which minimum royalties are creditable against its royalty obligation with respect to net sales of licensed products due in the year the minimum royalty is paid. If the Company or any of its affiliates sublicense any of the licensed patent rights to a third party, it will be obligated to pay Penn, for the benefit of the Licensors, a high single-digit to a mid ten's percentage of the consideration received in exchange for such sublicense, with the applicable percentage based upon the stage of development of the sublicensed product at the time it or the applicable affiliate enters into the sublicense. If the Company receives a rare pediatric disease priority review voucher from the FDA in connection with obtaining marketing approval for a licensed product and the Company subsequently uses such priority review voucher in connection with a different product candidate outside the scope of the BEST1 License Agreement, it will be obligated to pay Penn, for the benefit of the Licensors, aggregate payments in the low double-digit millions of dollars based on certain approval and commercial sales milestones with respect to such other product candidate. In addition, if it sells such a priority review voucher to a third party, it will be obligated to pay Penn, for the benefit of the Licensors, a high single-digit percentage of any consideration received from such third party in connection with such sale. The BEST1 License Agreement, unless earlier terminated by the Company or Penn or UFRF, will expire upon the expiration of the Company's obligation to pay royalties on net sales of licensed products. Before the effectiveness of an IND for a licensed product, the Company may terminate the BEST1 License Agreement with respect to such licensed product or in its entirety, at any time for any reason upon prior written notice to Penn and UFRF. Following the effectiveness of an IND for a licensed product, it may terminate the BEST1 License Agreement with respect to such licensed product by providing Penn prior written notice and a certification that it is ceasing all use, research and development and commercialization of such licensed product, subject to certain limited exceptions. It may also terminate the BEST1 License Agreement if Penn or UFRF materially breaches the BEST1 License Agreement and does not cure such breach within a specified cure period. Penn or UFRF may terminate the BEST1 License Agreement if the Company materially breaches the BEST1 License Agreement and does not cure such breach within a specified cure period, if it experiences a specified insolvency event, if it ceases to carry on the entirety of its business related to the licensed patent rights, if it ceases for more than four consecutive quarters to make any payment of earned royalties on net sales of licensed products following the commencement of commercialization thereof, unless such cessation is based on safety concerns that the Company is actively attempting to address, or if it, any of its affiliates or any of its sublicensees challenges or assists a third party in challenging the validity, scope, patentability, and/or enforceability of the licensed patent rights. If it materially breaches certain diligence obligations under the BEST1 License Agreement with respect to only one licensed product, then Penn and UFRF may only terminate its rights and licenses under the BEST1 License Agreement for such licensed product, but not for other licensed products. In addition to the exclusive license agreement, the Company and Penn also entered into a Master-Sponsored Research Agreement (the "BEST1 MSRA"), facilitated by the Penn Center for Innovation. Under the BEST1 MSRA, the Company and Penn are conducting preclinical studies of IC-200, as well as natural history studies of patients with BEST1-related IRDs. The total amount of funding for the sponsored research covered by statements of work under the BEST1 MSRA that the Company has committed to date and expects to commit to is in the low single-digit millions of dollars. License Agreement with University of Massachusetts for the miniCEP290 Program In July 2019, the Company entered into the miniCEP290 License Agreement with UMass by exercising its exclusive option rights under an option agreement and a sponsored research agreement that it previously entered into with UMass in February 2018. Under the miniCEP290 License Agreement, UMass granted it a worldwide, exclusive license under specified patent rights and specified biological materials and a non-exclusive license under specified know-how to make, have made, use, offer to sell, sell, have sold and import products for the treatment of diseases associated with mutations in the CEP290 gene, including LCA10. In July 2019, the Company issued to UMass 75,000 shares of its common stock following execution of the miniCEP290 License Agreement pursuant to an exemption from registration afforded by Section 4(a)(2) of the Securities Act. In September 2019, it paid UMass a $0.4 million upfront license fee, which was recorded as a research and development expense, and it paid UMass accrued patent prosecution expenses of approximately $18 thousand, which was recorded as a general and administrative expense. The Company has also agreed to pay UMass an annual license maintenance fee in the low double-digit thousands of dollars, which will be payable on an annual basis until the expiration of the royalty term for the licensed products. Furthermore, it has agreed to reimburse UMass for the costs and expenses of patent prosecution and maintenance related to the licensed patent rights. The Company has further agreed to pay UMass up to an aggregate of $14.75 million in cash and issue up to 75,000 shares of its common stock if it achieves specified clinical and regulatory milestones with respect to a licensed product. In addition, the Company has agreed to pay UMass up to an aggregate of $48.0 million if it achieves specified commercial sales milestones with respect to a licensed product. The Company is also obligated to pay UMass royalties at a low single-digit percentage of net sales of licensed products. Its obligation to pay royalties under the miniCEP290 License Agreement will continue on a licensed product-by-licensed product and country-by-country basis until the later of: (a) the expiration of the last-to-expire licensed patent rights covering the sale of the applicable licensed product in the country of sale, or (b) 10 years from the first commercial sale of the applicable licensed product in the country of sale. Beginning with the calendar year following receipt of marketing approval for a licensed product, it is also obligated to pay certain minimum royalties, not to exceed an amount in the mid-double-digit thousands of dollars on an annual basis, which minimum royalties are creditable against its royalty obligation with respect to net sales of licensed products due in the year the minimum royalty is paid. If the Company or any of its affiliates sublicenses any of the licensed patent rights or know-how to a third party, it will be obligated to pay UMass a high single-digit to a mid-tens percentage of the consideration received in exchange for such sublicense, with the applicable percentage based upon the stage of development of the licensed products at the time it or the applicable affiliate enters into the sublicense. If the Company receives a rare pediatric disease priority review voucher from the FDA in connection with obtaining marketing approval for a licensed product, and it subsequently uses such priority review voucher in connection with a different product candidate outside the scope of the miniCEP290 License Agreement, it will be obligated to pay UMass a low-tens percentage of the fair market value of the priority review voucher at the time of approval of such product candidate and a low-twenties percentage of the fair market value of the priority review voucher at the time of achievement of a specified commercial sales milestone for such other product candidate. In addition, if it sells such a priority review voucher to a third party, it will be obligated to pay UMass a low-thirties percentage of any consideration received from such third party in connection with such sale. The miniCEP290 License Agreement, unless earlier terminated by the Company or UMass, will expire upon the expiration of its obligation to pay royalties to UMass on net sales of licensed products. The Company may terminate the miniCEP290 License Agreement at any time for any reason upon prior written notice to UMass. It may also terminate the miniCEP290 License Agreement if UMass materially breaches the miniCEP290 License Agreement and does not cure such breach within a specified cure period. UMass may terminate the miniCEP290 License Agreement if the Company materially breaches the miniCEP290 License Agreement and does not cure such breach within a specified cure period.

Financing Agreement with Novo Holdings A/S	12 Months Ended
Financing Agreement with Novo Holdings A/S	Dec. 31, 2020
Related Party Transactions [Abstract]
Financing Agreement with Novo Holdings A/S	Financing Agreement with Novo Holdings A/S In May 2013, the Company entered into a Purchase and Sale Agreement (the "Novo Agreement") with Novo Holdings A/S ("Novo" and formerly Novo A/S), pursuant to which the Company obtained financing in three tranches in an aggregate amount equal to $125.0 million in return for the sale to Novo of aggregate royalties of a mid-single digit percentage on worldwide sales of (a) Fovista, (b) certain Fovista-related Products ("Fovista-Related Products"), and (c) certain other antagonists of platelet-derived growth factor ("PDGF"), if any, that the Company initiated development activities for prior to the fifth anniversary of the Novo Agreement (collectively, the "Anti-PDGF Royalty Products"). The Company received the cash payments from Novo in each of May 2013, January 2014 and November 2014. the Company received cash payments of $41.7 million, or $125.0 million in the aggregate. The $125.0 million in aggregate proceeds from the three financing tranches under the Novo Agreement represented the full funding available under the Novo Agreement, and prior to December 31, 2018, was recorded as a royalty purchase liability on the Company's Balance Sheet, in accordance with ASC 730, Research and Development. Because there was a significant related party relationship between the Company and Novo, the Company treated its obligation to make royalty payments under the Novo Agreement as an implicit obligation to repay the funds advanced by Novo. On December 31, 2018, the Company and Novo entered into a letter agreement (the "Novo Termination Agreement"), that terminated the Novo Agreement. As a result of the Novo Termination Agreement, Novo relinquished all rights to receive royalties based on net sales of Anti-PDGF Royalty Products. In exchange, the Company agreed to forbear from any future filing, prosecution, maintenance or enforcement of any intellectual property rights related to Anti-PDGF Royalty Products, and from granting any third party any right or license in any such intellectual property rights or clinical study data generated by or on behalf of the Company, its affiliates, licensees or sublicensees, for the development, manufacture or commercialization of Anti-PDGF Royalty Products or any other antagonists of PDGF. The foregoing restriction does not apply to gene therapies (so long as the Company does not grant any rights or licenses to intellectual property or clinical study data related to Fovista or Fovista-Related Products). The Company further agreed, until December 31, 2028, not to develop, manufacture, seek or obtain regulatory approval for, or commercialize any Anti-PDGF Royalty Products without the prior written consent of Novo. The foregoing restriction does not apply to any gene therapies (so long as the Company does not utilize data related to Fovista or Fovista-Related Products). As a result of the Novo Termination Agreement, the Company has no obligation to repay Novo the $125.0 million through future product royalties or any other development activities. Accordingly, the Company extinguished the $125.0 million royalty purchase liability from its Consolidated Balance Sheet at December 31, 2018 and recognized a related gain of $125.0 million in its Consolidated Statements of Operations for the year ended December 31, 2018. The extinguishment of the royalty purchase liability and the related gain did not impact the Company's cash balance during that period, as the Company had received the proceeds related to the royalty purchase liability in prior periods.

Property and Equipment

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment as of December 31, 2020 and 2019 were as follows:


	Useful Life (Years)	December 31, 2020		December 31, 2019
Manufacturing and clinical equipment	7 - 10	$	47	$	47
Computer, software and other office equipment	5	933		933
		980		980
Accumulated depreciation		(954)		(807)
Property and equipment, net		$	26	$	173

For the years ended December 31, 2020, 2019 and 2018, depreciation expense was $0.1 million, $0.2 million and $0.2 million, respectively.

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company's policy is to record interest and penalties on uncertain tax positions as income tax expense.

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A reconciliation of the statutory U.S. federal rate to the Company's effective tax rate is as follows:


	Years ended December 31,
	2020		2019		2018
Percent of pre-tax income:
U.S. federal statutory income tax rate	21.0	%	21.0	%	21.0	%
State taxes, net of federal benefit	14.8	%	10.9	%	18.5	%
Permanent items	0.2	%	(1.0)	%	4.0	%

Impact of state rate changes	0.1	%	0.1	%	(0.2)	%
Research and development credit	3.1	%	2.8	%	(2.4)	%

Change in valuation allowance	(34.8)	%	(33.6)	%	(42.6)	%
Effective income tax rate	4.4	%	0.2	%	(1.7)	%

The components of income tax benefit are as follows:


	Years ended December 31,
	2020		2019		2018
Current:
Federal	$	—	$	—	$	—
State	(3,695)		(111)		(1,063)
Deferred:
Federal	—		—		—
State	—		—		—
Income tax benefit	$	(3,695)	$	(111)	$	(1,063)

Significant components of the Company's deferred tax assets (liabilities) for 2020 and 2019 consist of the following:


	As of December 31,
	2020		2019
Deferred tax assets (liabilities)

License and technology payments	$	7,479	$	7,116
Share-based compensation	23,266		22,131
Accrued expenses	427		362
Right-of-use asset	(40)		(163)
Lease obligation	38		162
Depreciation	6		(18)
Federal and state net operating loss carryforwards	130,524		105,375
Research and development credits	9,959		7,353
Other	7		6
Deferred income tax assets	171,666		142,324
Valuation allowance	(171,666)		(142,324)
Net deferred tax assets	$	—	$	—

The Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible.

The Company incurred tax losses in 2020 and 2019. The Company has carried forward its federal and state tax losses due to the inability of carryback claims. Federal NOLs incurred prior to 2018 will begin to expire in 2034 if not utilized. Post 2017 Federal NOLs have an unlimited life. The state NOLs are expected to begin to expire in 2028. Due to the Company's history of losses and lack of other positive evidence to support taxable income, the Company has recorded a valuation allowance against those remaining deferred tax assets that are not expected to be realized. As of December 31, 2020, the Company has federal NOL carryforwards of approximately $445.0 million.

For the year ended December 31, 2020, the Company recorded a benefit from income taxes of $3.7 million to reflect the settlement of a local tax audit and the associated decrease in the Company's related uncertain tax position, including interest and penalties. For the years ended December 31, 2019 and 2018, the Company recorded an income tax benefit of $0.1 million and $1.1 million, respectively, due primarily to reflect the settlements of local tax audits. During 2019, the Company received $1.8 million related to the refund of the aforementioned AMT credits and recorded a tax receivable of $1.8 million to reflect the

refund of AMT credits it expects to receive over the next three years. On March 27, 2020, in response to the COVID-19 pandemic, the U.S. Congress enacted the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The CARES Act provides numerous tax provisions and other stimulus measures, including the immediate refund of minimum tax credits. The Company has recorded a current tax receivable of approximately $1.8 million in anticipation of this refund. During 2020, the Company applied for a refund of the remaining AMT credits of $1.8 million and anticipates receiving this refund in 2021.

The Company generated net income before income taxes for the year ended December 31, 2018. This income was due to the Novo Termination Agreement. With respect to the remaining deferred tax assets, except for the AMT credits previously discussed above, there was no change in the amount of assets realizable at December 31, 2020.

Pursuant to ASC 740, Income Taxes, the Company routinely evaluates the likelihood of success if challenged on income tax positions claimed on its income tax returns. During the year ended December 31, 2020, the Company reduced its uncertain tax liability by approximately $5.2 million following the settlement of state tax audits. The Company increased certain deferred tax assets by $0.3 million and increased the corresponding valuation allowance by an equivalent amount.

The Company's position with respect to uncertain tax positions is set forth below:


Opening balance	$	12,227
Gross amount of increases in unrecognized tax benefits during the period - current year provisions	—
Gross amount of increases in unrecognized tax benefits during the period - prior year provisions	—
Gross amount of decreases in unrecognized tax benefits during the period - other	(659)
Decreases due to settlement with tax authorities during the period	(4,845)
Reduction of unrecognized tax benefits due to expiration of the state of limitations during the period	—
Closing Balance	$	6,723

The Company will continue to evaluate its ability to realize its deferred tax assets on a periodic basis and will adjust such amounts in light of changing facts and circumstances including, but not limited to, future projections of taxable income, tax legislation, rulings by relevant tax authorities, the progress of ongoing tax audits and the regulatory approval of product candidates currently under development. Any additional changes to the valuation allowance recorded on deferred tax assets in the future would impact the Company’s income taxes.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Operating Leases

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Operating Leases

The Company's principal executive offices was previously at One Penn Plaza, New York, NY. The term of this lease expired in December 2020.

Effective December 1, 2020, the Company changed the location of its principal executive offices to Five Penn Plaza, New York, NY. The Company entered into an office service agreement with Regus Management Group, LLC for use of office space at this location. This agreement currently expires in May 2021.

The Company leases office space located in Cranbury, New Jersey under non-cancelable operating lease arrangements. The lease for the Company's Cranbury office commenced in February 2020 and expires in February 2023.

In December 2020, the Company entered into a lease agreement for office space located in Parsippany, New Jersey. The Company will recognize a right-to-use asset and lease liability when the term of the lease commences, which is expected to be in early 2021. The term of the lease for the Company's Parsippany office will expire in August 2023.

For the years ended December 31, 2020, 2019 and 2018, lease and rent expense was $0.6 million, $1.0 million, and $0.8 million, respectively. Cash paid from operating cash flows for amounts included in the measurement of lease liabilities was $0.6 million and $1.0 million for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020, the Company's operating leases had a weighted average remaining lease term of 2.1 years and a weighted average estimated incremental borrowing rate of 3.4% .

The following presents the maturity of the Company's operating lease liabilities as of December 31, 2020:


	December 31, 2020
2021	$	57
2022	58
2023	5

Total minimum lease payments	120
Less imputed interest	(5)
Present value of minimum lease payments	115
Less current portion	54
Total long-term operating lease liabilities	$	61

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Zimura - Archemix Corp. The Company is party to an agreement with Archemix Corp., or Archemix, under which the Company in-licensed rights in certain patents, patent applications and other intellectual property related to Zimura and pursuant to which the Company may be required to pay sublicense fees and make milestone payments (the "C5 License Agreement"). For each anti-C5 aptamer product that the Company may develop under the agreement, including Zimura, the Company is obligated to make additional payments to Archemix of up to an aggregate of $50.5 million if the Company achieves specified development, clinical and regulatory milestones, with $24.5 million of such payments relating to a first indication, $23.5 million of such payments relating to second and third indications and $2.5 million of such payments relating to sustained delivery applications. Under the C5 License Agreement, the Company is also obligated to make additional payments to Archemix of up to an aggregate of $22.5 million if the Company achieves specified commercial milestones based on net product sales of all anti-C5 licensed products. The Company is also obligated to pay Archemix a double-digit percentage of specified non-royalty payments the Company may receive from any sublicensee of its rights under the C5 License Agreement. The Company is not obligated to pay Archemix a running royalty based on net product sales in connection with the C5 License Agreement. IC-100 - University of Florida Research Foundation and the University of Pennsylvania Under its exclusive license agreement with UFRF and Penn for rights to IC-100, the Company is obligated to make payments to UFRF, for the benefit of the Licensors, of up to an aggregate of $23.5 million if the Company achieves specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product and up to an aggregate of an additional $70.0 million if the Company achieves specified commercial sales milestones with respect to a licensed product. The Company is also obligated to pay UFRF, for the benefit of the Licensors, a low single-digit percentage of net sales of licensed products. The Company is also obligated to pay UFRF, for the benefit of the Licensors, a double-digit percentage of specified non-royalty payments the Company may receive from any third-party sublicensee of the licensed patent rights. Further, if the Company receives a rare pediatric disease priority review voucher from the FDA in connection with obtaining marketing approval for a licensed product and the Company subsequently uses such priority review voucher in connection with a different product candidate, the Company will be obligated to pay UFRF, for the benefit of the Licensors, aggregate payments in the low double-digit millions of dollars based on certain approval and commercial sales milestones with respect to such other product candidate. In addition, if the Company sells such a priority review voucher to a third party, the Company will be obligated to pay UFRF, for the benefit of the Licensors, a low double-digit percentage of any consideration received from such third party in connection with such sale. IC-200 - University of Pennsylvania and the University of Florida Research Foundation Under its exclusive license agreement with Penn and UFRF for rights to IC-200, the Company is obligated to make payments to Penn, for the benefit of the Licensors, of up to an aggregate of $15.7 million if the Company achieves specified clinical, marketing approval and reimbursement approval milestones with respect to one licensed product and up to an aggregate of an additional $3.1 million if the Company achieves these same milestones with respect to a different licensed product. In addition, the Company is obligated to make payments to Penn, for the benefit of the Licensors, of up to an aggregate of $48.0 million if the Company achieves specified commercial sales milestones with respect to one licensed product and up to an aggregate of an additional $9.6 million if the Company achieves these same milestones with respect to a different licensed product. The Company is also obligated to pay Penn, for the benefit of the Licensors, a low single-digit percentage of net sales of licensed products. The Company is also obligated to pay Penn, for the benefit of the Licensors, a high single-digit to a mid-ten's percentage of specified non-royalty payments the Company may receive from any third-party sublicensee of the licensed patent rights, with the applicable percentage based upon the stage of development of the sublicensed product at the time the Company enters into the sublicense. Further, if the Company receives a rare pediatric disease priority review voucher from the FDA in connection with obtaining marketing approval for a licensed product and the Company subsequently uses such priority review voucher in connection with a different product candidate outside the scope of the agreement, the Company will be obligated to pay Penn, for the benefit of the Licensors, aggregate payments in the low double-digit millions of dollars based on certain approval and commercial sales milestones with respect to such other product candidate. In addition, if the Company sells such a priority review voucher to a third party, the Company will be obligated to pay Penn, for the benefit of the Licensors, a high single-digit percentage of any consideration received from such third party in connection with such sale. miniCEP290 Program - University of Massachusetts Under the miniCEP290 License Agreement, the Company is obligated to pay UMass up to an aggregate of $14.75 million in cash and issue up to 75,000 shares of common stock of the Company if the Company achieves specified clinical and regulatory milestones with respect to a licensed product. In addition, the Company is obligated to pay UMass up to an aggregate of $48.0 million if the Company achieves specified commercial sales milestones with respect to a licensed product. The Company is also obligated to pay UMass royalties at a low single-digit percentage of net sales of licensed products. If the Company or any of its affiliates sublicenses any of the licensed patent rights or know-how to a third party, the Company will be obligated to pay UMass a high single-digit to a mid-tens percentage of the consideration received in exchange for such sublicense, with the applicable percentage based upon the stage of development of the licensed products at the time the Company or the applicable affiliate enters into the sublicense. If the Company receives a priority review voucher from the FDA in connection with obtaining marketing approval for a licensed product, and the Company subsequently uses such priority review voucher in connection with a different product candidate outside the scope of the agreement, the Company will be obligated to pay UMass a low-tens percentage of the fair market value of the priority review voucher at the time of approval of such product candidate and a low-twenties percentage of the fair market value of the priority review voucher at the time of achievement of a specified commercial sales milestone for such product candidate. In addition, if the Company sells such a priority review voucher to a third party, the Company will be obligated to pay UMass a low-thirties percentage of any consideration received from such third party in connection with such sale. IC-500 - Former Equityholders of Inception 4 Under the Inception 4 Merger Agreement, the Company is obligated to make payments to the former equityholders of Inception 4 of up to an aggregate of $105 million, subject to the terms and conditions of the Inception 4 Merger Agreement, if the Company achieves certain specified clinical and regulatory milestones with respect to a product candidate from its HtrA1 inhibitor program, including IC-500, with $45 million of such potential payments relating to GA and $60 million of such potential payments relating to wet AMD. Under the Inception 4 Merger Agreement, the Company does not owe any commercial milestones or royalties based on net sales. The future milestone payments will be payable in the form of shares of the Company's common stock, calculated based on the price of its common stock over a five-trading day period preceding the achievement of the relevant milestone, unless and until the issuance of such shares would, together with all other shares issued in connection with the Inception 4 Merger, exceed an overall maximum limit of approximately 7.2 million shares, which is equal to 19.9% of the number of issued and outstanding shares of the Company's common stock as of the close of business on the business day prior to the closing date of the Inception 4 Merger, and will be payable in cash thereafter. The Inception 4 Merger Agreement also includes customary indemnification obligations to the former equityholders of Inception 4, including for breaches of the representations and warranties, covenants and agreements of the Company and its subsidiaries (other than Inception 4) in the Inception 4 Merger Agreement. Employment Contracts The Company also has letter agreements with certain employees that require the funding of a specific level of payments if certain events, such as a termination of employment in connection with a change in control or termination of employment by the employee for good reason or by the Company without cause, occur. Contract Service Providers In addition, in the course of normal business operations, the Company has agreements with contract service providers to assist in the performance of the Company’s research and development and manufacturing activities. Expenditures to CROs and CDMOs represent significant costs in preclinical and clinical development. Subject to required notice periods and the Company’s obligations under binding purchase orders and any cancellation fees that the Company may be obligated to pay, the Company can elect to discontinue the work under these agreements at any time. Legal Proceedings On January 11, 2017, a putative class action lawsuit was filed against the Company and certain of its current and former executive officers in the United States District Court for the Southern District of New York, captioned Frank Micholle v. IVERIC bio, Inc., et al., No. 1:17-cv-00210. On March 9, 2017, a related putative class action lawsuit was filed against the Company and the same group of its current and former executive officers in the United States District Court for the Southern District of New York, captioned Wasson v. IVERIC bio, Inc., et al., No. 1:17-cv-01758. These cases were consolidated on March 13, 2018. On June 4, 2018, the lead plaintiff filed a consolidated amended complaint (the “CAC”). The CAC purports to be brought on behalf of shareholders who purchased the Company’s common stock between March 2, 2015 and December 12, 2016. The CAC generally alleges that the Company and certain of its officers violated Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making allegedly false and/or misleading statements concerning the results of the Company’s Phase 2b trial and the prospects of the Company’s Phase 3 trials for Fovista in combination with anti-VEGF agents for the treatment of wet AMD. The CAC seeks unspecified damages, attorneys’ fees, and other costs. The Company and individual defendants filed a motion to dismiss the CAC on July 27, 2018. On September 18, 2019, the court issued an order dismissing some, but not all, of the allegations in the CAC. On November 18, 2019, the Company and the individual defendants filed an answer to the complaint. On June 12, 2020, the lead plaintiff filed a motion for class certification. On August 11, 2020, the defendants filed a notice of non-opposition to lead plaintiff's motion for class certification. This case is currently in the discovery phase. On February 7, 2018, a shareholder derivative action was filed against the members of the Company’s Board of Directors in the New York Supreme Court Commercial Division, captioned Cano v. Guyer, et al., No. 650601/2018. The complaint alleges that the defendants breached their fiduciary duties to the Company by adopting a compensation plan that overcompensates the non-employee members of the Board relative to boards of companies of comparable market capitalization and size. The complaint also alleges that the defendants were unjustly enriched as a result of the alleged conduct. The complaint purports to seek unspecified damages, on behalf of the Company, attorneys’ fees, and other costs, as well as an order directing the Company to reform and improve its corporate governance and internal procedures to comply with applicable laws. The Company filed a motion to dismiss this case on May 14, 2018. On June 4, 2018, the plaintiff filed an amended complaint. On June 25, 2018, the Company filed a renewed motion to dismiss this case. On December 3, 2018, the parties filed a stipulation of settlement that contemplates that the Company will adopt certain compensation-related governance reforms and does not obligate the defendants or the Company to pay any monetary damages. The court approved the settlement at a hearing on March 12, 2019. As part of the settlement, in April 2019 the Company paid $0.3 million in fees and costs to plaintiff's counsel. As contemplated by the settlement, the Company's board of directors adopted certain compensation-related governance reforms, including a non-employee director compensation policy, which its stockholders approved on May 15, 2019 at its 2019 annual meeting. On August 31, 2018, a shareholder derivative action was filed against current and former members of the Company's Board of Directors and certain current and former officers of the Company in the United States District Court for the Southern District of New York, captioned Luis Pacheco v. David R. Guyer, et al., Case No. 1:18-cv-07999. The complaint, which is based substantially on the facts alleged in the CAC, alleges that the defendants breached their fiduciary duties to the Company and wasted the Company's corporate assets by failing to oversee the Company's business, and also alleges that the defendants were unjustly enriched as a result of the alleged conduct, including through receipt of bonuses, stock options and similar compensation from the Company, and through sales of the Company's stock between March 2, 2015 and December 12, 2016. The complaint purports to seek unspecified damages on the Company's behalf, attorneys’ fees, and other costs, as well as an order directing the Company to reform and improve its corporate governance and internal procedures to comply with applicable laws, including submitting certain proposed amendments to the Company's corporate charter, bylaws and corporate governance policies for vote by the Company's stockholders. On December 14, 2018, the Company filed a motion to dismiss the complaint. On September 19, 2019, the court denied its motion to dismiss this complaint. This matter was subsequently referred to a special litigation committee of the Company's board of directors. On February 18, 2020, the Company filed an answer to the complaint. The Company and the plaintiff agreed to stay this litigation while the special litigation committee conducts its investigation. On May 4, 2020, the court approved the stipulation and stayed the litigation through November 1, 2020. By agreement of the parties, the court has since extended the stay through March 13, 2021. The Company also entered into tolling agreements with the defendant directors to December 2021. On October 16, 2018, the Company’s board of directors received a shareholder demand to investigate and commence legal proceedings against certain members of the Company’s board of directors. The demand alleges facts that are substantially similar to the facts alleged in the CAC and the Pacheco complaint and asserts claims that are substantially similar to the claims asserted in the Pacheco complaint. On January 30, 2019, the Company’s board of directors received a second shareholder demand from a different shareholder to investigate and commence legal proceedings against certain current and former members of the Company’s board of directors based on allegations that are substantially similar to the allegations contained in the first demand letter. These shareholder demands have been referred to a demand review committee of the Company's board of directors. The Company has entered into tolling agreements with the directors named in the demands to December 2021. The Company denies any and all allegations of wrongdoing and intends to vigorously defend against these lawsuits. The Company is unable, however, to predict the outcome of these matters at this time. Moreover, any conclusion of these matters in a manner adverse to the Company and for which it incurs substantial costs or damages not covered by the Company's directors’ and officers’ liability insurance would have a material adverse effect on its financial condition and business. In addition, the litigation could adversely impact the Company's reputation and divert management’s attention and resources from other priorities, including the execution of its business plan and strategies that are important to the Company's ability to grow its business, any of which could have a material adverse effect on the Company's business.

Stock-Based Compensation and Compensation Plans

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation and Compensation Plans

The Company adopted its 2007 Stock Incentive Plan (the "2007 Plan") for employees, non-employee directors and consultants for the purpose of advancing the interests of the Company's stockholders by enhancing its ability to attract, retain and motivate persons who are expected to make important contributions to the Company. The 2007 Plan provided for the granting of stock option awards, RSUs, and other stock-based and cash-based awards. Following the effectiveness of the 2013 Stock Incentive Plan described below in connection with the closing of the Company's initial public offering, the Company is no longer granting additional awards under the 2007 Plan.

In August 2013, the Company's board of directors adopted, and the Company's stockholders approved, the 2013 Stock Incentive Plan (the "2013 Plan"), which became effective immediately prior to the closing of the Company's initial public offering. In June 2015, the Company’s board of directors adopted a first amendment to the 2013 Plan. The 2013 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, RSUs, restricted stock awards and other stock-based awards. Upon the effectiveness of the 2013 Plan, the number of shares of the Company's common stock that were reserved for issuance under the 2013 Plan was the sum of (1) a number of shares (up to a maximum of approximately 3,359,641 shares) that is equal to the sum of 739,317 shares (the number of shares of the Company's common stock then available for issuance under the 2007 Plan), and such number of shares of the Company's common stock that are subject to outstanding awards under the 2007 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right, plus (2) an annual increase, to be added the first business day of each fiscal year, beginning with the fiscal year ending December 31, 2014 and continuing until, and including, the fiscal year ending December 31, 2023, equal to the lowest of 2,542,372 shares of the Company's common stock, 4% of the number of shares of the Company's common stock outstanding on the first day of the fiscal year and an amount

determined by its board of directors. The Company's employees, officers, directors, consultants and advisors are eligible to receive awards under the 2013 Plan. However, incentive stock options may only be granted to employees of the Company.

Annual increases under the evergreen provisions of the 2013 Plan have resulted in the addition of an aggregate of approximately 13,081,000 additional shares to the 2013 Plan, including for 2021, an increase of approximately 2,542,000 shares. As of December 31, 2020, the Company had approximately 421,000 shares available for grant under the 2013 Plan.

In October 2019, the Company's board of directors adopted the 2019 Inducement Stock Incentive Plan (the “2019 Inducement Plan”) to reserve 1,000,000 shares of its common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such individuals’ entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. In March 2020, the Company's board of directors amended the 2019 Inducement Plan to reserve an additional 1,000,000 shares of its common stock for issuance under the plan and in February 2021, the Company's board of directors further amended the 2019 Inducement Plan to reserve an additional 600,000 shares of its common stock for issuance under the plan. The terms and conditions of the 2019 Inducement Plan are substantially similar to those of the 2013 Plan. As of December 31, 2020, the Company had approximately 555,000 shares available for grant under the 2019 Inducement Plan.

In April 2016, the board of directors adopted the ESPP pursuant to which the Company may sell up to an aggregate of 1,000,000 shares of common stock. The ESPP was approved by the Company’s stockholders in June 2016. The ESPP allows eligible employees to purchase common stock at a price per share equal to 85% of the lower of the fair market value of the common stock at the beginning or end of each six month offering period during the term of the ESPP. The first offering period began in September 2016.

A summary of the stock option activity, weighted average exercise prices, options outstanding and exercisable as of December 31, 2020, 2019 and 2018 is as follows (in thousands except weighted average exercise price):


	Years ended December 31,
	2020			2019			2018
	Common Stock Options	Weighted Average Exercise Price		Common Stock Options	Weighted Average Exercise Price		Common Stock Options	Weighted Average Exercise Price
Outstanding, December 31, 2019	6,780	$	10.89	5,903	$	13.72	5,284	$	19.58
Granted	2,630	$	6.10	1,610	$	4.26	1,293	$	1.67
Exercised	(109)	$	2.89	(80)	$	2.66	—	$	—
Expired or forfeited	(373)	$	19.49	(653)	$	21.16	(674)	$	36.54
Outstanding, December 31, 2020	8,928	$	9.22	6,780	$	10.89	5,903	$	13.72


	Years ended December 31,
	2020		2019		2018
Options exercisable at December 31, 2020	4,462		3,317		2,709
Weighted average grant date fair value (per share) of options granted during the period	$	13.51	$	3.37	$	1.20

As of December 31, 2020, there were approximately 8,526,000 options outstanding, net of estimated forfeitures, that had vested or are expected to vest. The weighted-average exercise price of these options was $9.42 per option; the weighted-average remaining contractual life of these options was 7.6 years; and the aggregate intrinsic value of these options was approximately $20.6 million. A summary of the stock options outstanding and exercisable as of December 31, 2020 is as

follows (in thousands except exercise prices and weighted average exercise price):


			December 31, 2020
			Options Outstanding			Options Exercisable
Range of Exercise Prices	Total Options Outstanding		Weighted Average Remaining Life (Years)	Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$1.13-$2.90	1,352		7.7	$	1.68	808		$	1.79
$2.91-$3.18	2,053		7.5	$	2.99	1,180		$	2.94
$3.19-$4.88	1,790		7.7	$	4.24	1,022		$	4.39
$4.89-$8.77	2,491		9.6	$	6.64	211		$	5.24
$8.78-$73.22	1,242		3.8	$	40.08	1,241		$	40.08
	8,928		7.6	$	9.22	4,462		$	13.51

Aggregate Intrinsic Value	$	20,553				$	11,741

Cash proceeds from, and the aggregate intrinsic value of, stock options exercised during the years ended December 31, 2020, 2019 and 2018, respectively, were as follows:


	Years ended December 31,
	2020		2019		2018
Cash proceeds from options exercised	$	314	$	192	$	—
Aggregate intrinsic value of options exercised	$	393	$	135	$	—

In connection with stock option awards granted to employees, the Company recognized approximately $4.7 million, $5.9 million and $7.6 million in share-based compensation expense during the years ended December 31, 2020, 2019 and 2018, respectively, net of expected forfeitures. As of December 31, 2020, there were approximately $8.6 million of unrecognized compensation costs, net of estimated forfeitures, related to stock option awards granted to employees, which are expected to be recognized over a remaining weighted average period of 5.8 years.

In connection with stock option awards granted to consultants, the Company recognized approximately $0.2 million, $0.3 million and $0.2 million in share-based compensation expense during the years ended December 31, 2020, 2019 and 2018, respectively, net of expected forfeitures. As of December 31, 2020, there were approximately $0.1 million of unrecognized compensation costs, net of estimated forfeitures, related to stock option awards granted to consultants, which are expected to be recognized over a remaining weighted average period of 2.4 years.

The following table presents a summary of the Company's outstanding RSU awards granted as of December 31, 2020 (in thousands except weighted average grant-date fair value):


	Restricted Stock Units	Weighted Average Grant-Date Fair Value
Outstanding, December 31, 2019	1,481	$	7.79
Awarded	1,232	$	6.06
Vested	(657)	$	7.20
Forfeited	(98)	$	6.74
Outstanding, December 31, 2020	1,958	$	6.95

As of December 31, 2020, there were approximately 1,725,000 RSUs outstanding, net of estimated forfeitures, that are expected to vest. The weighted-average fair value of these RSUs was $5.25 per share; and the aggregate intrinsic value of these RSUs was approximately $11.9 million.

In connection with RSUs granted to employees, the Company recognized approximately $3.3 million, $3.0 million and $3.3 million in share-based compensation expense during the years ended December 31, 2020, 2019 and 2018, respectively, net of expected forfeitures. As of December 31, 2020, there was approximately $14.4 million of unrecognized compensation costs, net of estimated forfeitures, related to RSUs granted to employees, which are expected to be recognized over a remaining weighted average period of 2.0 years. The total fair value of the RSUs that vested during the year ended December 31, 2020 was $4.6 million.

In connection with RSUs granted to consultants, the Company recognized approximately $0.1 million in share-based compensation expense during the year ended December 31, 2020, net of expected forfeitures. In connection with RSUs granted to consultants, the Company recognized approximately a de minimis amount in share-based compensation expense during the year ended December 31, 2019. As of December 31, 2020, there were approximately $0.1 million of unrecognized compensation costs, net of estimated forfeitures, related to RSUs granted to consultants, which are expected to be recognized over a remaining weighted average period of 2.9 years.

In connection with the ESPP made available to employees, the Company recognized approximately $0.1 million and $0.1 million of share-based compensation expense during the years ended December 31, 2020 and December 31, 2019, respectively, net of expected forfeitures. As of December 31, 2020, there was a de minimis amount of unrecognized compensation costs, net of estimated forfeitures, related to the ESPP, which are expected to be recognized over 0.2 years. There were 76,402 shares of common stock issued under the ESPP during the year ended December 31, 2020. Cash proceeds from ESPP purchases were approximately $147 thousand during the year ended December 31, 2020. There were 70,466 shares of common stock issued under the ESPP during the year ended December 31, 2019. As of December 31, 2020, 805,361 shares were available for future purchases under the ESPP.

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2020
Retirement Benefits [Abstract]
Employee Benefit Plan	Employee Benefit PlanThe Company maintains a defined contribution 401(k) plan available to employees. Employee contributions are voluntary and are determined on an individual basis, limited by the maximum amounts allowable under federal tax regulations. The Company's matching contributions to employees totaled approximately $0.3 million, $0.2 million and $0.2 million during the years ended December 31, 2020, 2019 and 2018, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

+ Details

Selected Quarterly Financial Information (unaudited)

12 Months Ended

Dec. 31, 2020

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Information (unaudited)

The following is a summary of the quarterly results of operations for the years ended December 31, 2020 and 2019:


	2020
	March 31		June 30		September 30		December 31

Research and development expenses	$	13,750	$	12,720	$	18,841	$	17,473
General and administrative expenses	4,998		6,289		6,643		8,022
Loss from operations	(18,748)		(19,009)		(25,484)		(25,495)
Net income (loss) attributable to common stockholders	$	(15,076)	$	(18,589)	$	(25,450)	$	(25,432)
Basic earnings (loss) per common share	$	(0.28)	$	(0.32)	$	(0.27)	$	(0.27)
Diluted earnings (loss) per common share	$	(0.28)	$	(0.32)	$	(0.27)	$	(0.27)


	2019
	March 31		June 30		September 30		December 31

Research and development expenses	$	7,685	$	10,009	$	10,383	$	11,567
General and administrative expenses	5,481		5,198		4,674		6,275
Income (loss) from operations	(13,166)		(15,207)		(15,057)		(17,842)
Net income (loss) attributable to common stockholders	$	(12,501)	$	(14,443)	$	(14,437)	$	(17,478)
Basic earnings (loss) per common share	$	(0.30)	$	(0.35)	$	(0.35)	$	(0.39)
Diluted earnings (loss) per common share	$	(0.30)	$	(0.35)	$	(0.35)	$	(0.39)

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation and Consolidation

the Company's financial position for the periods presented.

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Segment and geographic information

Segment and geographic information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.

Use of Estimates

Cash and Cash Equivalents

Cash, Cash Equivalents and Available for Sale Securities

Available for Sale Securities

Concentration of Credit Risk

The Company believes it is not exposed to significant credit risk on its cash and cash equivalents.

Concentration of Suppliers

Foreign Currency Translation

Financial Instruments

Leases

Property and Equipment

Research and Development

•employee-related expenses for employees dedicated to research and development activities, including salaries, benefits and share-based compensation expense.

Income Taxes

Share-Based Compensation

then all previously recorded stock-based compensation expense associated with such options will be reversed during the period in which the Company makes this determination.

Stock Options


	Years ended December 31,
	2020	2019	2018
Expected common stock price volatility	118%	110%	85%
Risk-free interest rate	0.22%-1.34%	1.38%-2.54%	2.39%-2.95%
Expected term of options (years)	4.6	4.8	6.0
Expected dividend yield	—	—	—

RSUs

The Company estimates the fair value of RSUs granted to employees using the closing market price of the Company's common stock on the date of grant.

ESPP


	Years ended December 31,
	2020		2019		2018
Research and development	$	4,166	$	4,260	$	4,967
General and administrative	4,157		4,920		6,105
Total	$	8,323	$	9,180	$	11,072

Recently Adopted and Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of Weighted-average Aassumptions Used to Estimate Grant Date Fair Value of Stock Options


	Years ended December 31,
	2020	2019	2018
Expected common stock price volatility	118%	110%	85%
Risk-free interest rate	0.22%-1.34%	1.38%-2.54%	2.39%-2.95%
Expected term of options (years)	4.6	4.8	6.0
Expected dividend yield	—	—	—

Schedule of Share-based Compensation Expense


	Years ended December 31,
	2020		2019		2018
Research and development	$	4,166	$	4,260	$	4,967
General and administrative	4,157		4,920		6,105
Total	$	8,323	$	9,180	$	11,072

Net Loss Per Common Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Net Income (Loss) per Common Share

The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods indicated:


	Years ended December 31,
	2020		2019		2018
Basic and diluted net income (loss) per common share calculation:
Net income (loss)	$	(84,547)	$	(58,859)	$	63,087
Weighted average common shares outstanding - basic	74,185		42,224		37,061
Plus: net effect of dilutive stock options and unvested restricted stock units	—		—		27
Weighted average common shares outstanding - dilutive	74,185		42,224		37,088
Net income (loss) per common share - basic	$	(1.14)	$	(1.39)	$	1.70
Net income (loss) per common share - diluted	$	(1.14)	$	(1.39)	$	1.70

Schedule of Potentially Dilutive Securities Excluded from the Computations of Diluted Weighted Average Common Shares Outstanding


	Years ended December 31,
	2020	2019	2018
Stock options outstanding	8,928	6,780	5,873
Restricted stock units	1,958	1,481	601
Total	10,886	8,261	6,474

Cash and Cash Equivalents (Tables)

12 Months Ended

Dec. 31, 2020

Cash and Cash Equivalents [Abstract]

Schedule of Available-for-Sale Securities

Available for sale securities, including carrying value and estimated fair values, are summarized as follows:


	As of December 31, 2020
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
U.S. Treasury securities	$	54,225	$	8	$	—	$	54,233
Corporate debt securities	79,282		4		(10)		79,276
Asset-backed securities	10,164		1		—		10,165
Total	$	143,671	$	13	$	(10)	$	143,674

Schedule of Changes in Accumulated Other Comprehensive Income (Loss) for Unrealized Loss on Available for Sale Securities

The changes in accumulated other comprehensive income (loss) associated with the unrealized loss on available for sale securities for the years ended December 31, 2020 and December 31, 2019 were as follows:


	Years ended December 31,
	2020		2019
Beginning balance	$	—	$	—
Current period changes in fair value before reclassifications, net of tax	3		—
Amounts reclassified from accumulated other comprehensive income, net of tax	—		—
Total other comprehensive income	$	3	$	—
Ending balance	$	3	$	—

Fair Value Measurements - (Tables)

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis


	Fair Value Measurement Using
	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Investments in money market funds*	$	58,042	$	—	$	—

Investments in U.S. Treasury securities	$	54,233	$	—	$	—
Investments in corporate debt securities*	$	—	$	79,275	$	—
Investments in asset-backed securities	$	—	$	10,166	$	—


	Fair Value Measurement Using
	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Investments in money market funds*	$	108,585	$	—	$	—
Investments in corporate debt securities*	$	—	$	13,875	$	—

*Investments in money market funds and corporate debt securities with maturities less than 90 days are reflected in cash and cash equivalents in the accompanying Balance Sheets.

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment as of December 31, 2020 and 2019 were as follows:


	Useful Life (Years)	December 31, 2020		December 31, 2019
Manufacturing and clinical equipment	7 - 10	$	47	$	47
Computer, software and other office equipment	5	933		933
		980		980
Accumulated depreciation		(954)		(807)
Property and equipment, net		$	26	$	173

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Reconciliation of the Statutory U.S. Federal Rate to the Company's Effective Tax Rate

A reconciliation of the statutory U.S. federal rate to the Company's effective tax rate is as follows:


	Years ended December 31,
	2020		2019		2018
Percent of pre-tax income:
U.S. federal statutory income tax rate	21.0	%	21.0	%	21.0	%
State taxes, net of federal benefit	14.8	%	10.9	%	18.5	%
Permanent items	0.2	%	(1.0)	%	4.0	%

Impact of state rate changes	0.1	%	0.1	%	(0.2)	%
Research and development credit	3.1	%	2.8	%	(2.4)	%

Change in valuation allowance	(34.8)	%	(33.6)	%	(42.6)	%
Effective income tax rate	4.4	%	0.2	%	(1.7)	%

Schedule of Components of Income Tax (Benefit) Expense

The components of income tax benefit are as follows:


	Years ended December 31,
	2020		2019		2018
Current:
Federal	$	—	$	—	$	—
State	(3,695)		(111)		(1,063)
Deferred:
Federal	—		—		—
State	—		—		—
Income tax benefit	$	(3,695)	$	(111)	$	(1,063)

Schedule of Significant Components of the Company's Deferred Tax Assets (Liabilities)

Significant components of the Company's deferred tax assets (liabilities) for 2020 and 2019 consist of the following:


	As of December 31,
	2020		2019
Deferred tax assets (liabilities)

License and technology payments	$	7,479	$	7,116
Share-based compensation	23,266		22,131
Accrued expenses	427		362
Right-of-use asset	(40)		(163)
Lease obligation	38		162
Depreciation	6		(18)
Federal and state net operating loss carryforwards	130,524		105,375
Research and development credits	9,959		7,353
Other	7		6
Deferred income tax assets	171,666		142,324
Valuation allowance	(171,666)		(142,324)
Net deferred tax assets	$	—	$	—

Schedule of Position With Respect to Uncertain Tax Positions

The Company's position with respect to uncertain tax positions is set forth below:


Opening balance	$	12,227
Gross amount of increases in unrecognized tax benefits during the period - current year provisions	—
Gross amount of increases in unrecognized tax benefits during the period - prior year provisions	—
Gross amount of decreases in unrecognized tax benefits during the period - other	(659)
Decreases due to settlement with tax authorities during the period	(4,845)
Reduction of unrecognized tax benefits due to expiration of the state of limitations during the period	—
Closing Balance	$	6,723

Operating Leases (Tables)

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Schedule of Operating Lease Liability Maturities

The following presents the maturity of the Company's operating lease liabilities as of December 31, 2020:


	December 31, 2020
2021	$	57
2022	58
2023	5

Total minimum lease payments	120
Less imputed interest	(5)
Present value of minimum lease payments	115
Less current portion	54
Total long-term operating lease liabilities	$	61

Stock-Based Compensation and Compensation Plans (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Summary of the Stock Option Activity Including Weighted Average Exercise Prices, Options Outstanding and Exercisable


	Years ended December 31,
	2020			2019			2018
	Common Stock Options	Weighted Average Exercise Price		Common Stock Options	Weighted Average Exercise Price		Common Stock Options	Weighted Average Exercise Price
Outstanding, December 31, 2019	6,780	$	10.89	5,903	$	13.72	5,284	$	19.58
Granted	2,630	$	6.10	1,610	$	4.26	1,293	$	1.67
Exercised	(109)	$	2.89	(80)	$	2.66	—	$	—
Expired or forfeited	(373)	$	19.49	(653)	$	21.16	(674)	$	36.54
Outstanding, December 31, 2020	8,928	$	9.22	6,780	$	10.89	5,903	$	13.72


	Years ended December 31,
	2020		2019		2018
Options exercisable at December 31, 2020	4,462		3,317		2,709
Weighted average grant date fair value (per share) of options granted during the period	$	13.51	$	3.37	$	1.20

Summary of the Stock Options Outstanding and Exercisable

A summary of the stock options outstanding and exercisable as of December 31, 2020 is as

follows (in thousands except exercise prices and weighted average exercise price):


			December 31, 2020
			Options Outstanding			Options Exercisable
Range of Exercise Prices	Total Options Outstanding		Weighted Average Remaining Life (Years)	Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$1.13-$2.90	1,352		7.7	$	1.68	808		$	1.79
$2.91-$3.18	2,053		7.5	$	2.99	1,180		$	2.94
$3.19-$4.88	1,790		7.7	$	4.24	1,022		$	4.39
$4.89-$8.77	2,491		9.6	$	6.64	211		$	5.24
$8.78-$73.22	1,242		3.8	$	40.08	1,241		$	40.08
	8,928		7.6	$	9.22	4,462		$	13.51

Aggregate Intrinsic Value	$	20,553				$	11,741

Schedule of Cash Proceeds From, and the Aggregate Intrinsic Value of, Stock Options Exercised

Cash proceeds from, and the aggregate intrinsic value of, stock options exercised during the years ended December 31, 2020, 2019 and 2018, respectively, were as follows:


	Years ended December 31,
	2020		2019		2018
Cash proceeds from options exercised	$	314	$	192	$	—
Aggregate intrinsic value of options exercised	$	393	$	135	$	—

Summary of the Company's Outstanding Shares of RSU Awards

The following table presents a summary of the Company's outstanding RSU awards granted as of December 31, 2020 (in thousands except weighted average grant-date fair value):


	Restricted Stock Units	Weighted Average Grant-Date Fair Value
Outstanding, December 31, 2019	1,481	$	7.79
Awarded	1,232	$	6.06
Vested	(657)	$	7.20
Forfeited	(98)	$	6.74
Outstanding, December 31, 2020	1,958	$	6.95

Selected Quarterly Financial Information (unaudited) (Tables)

12 Months Ended

Dec. 31, 2020

Quarterly Financial Information Disclosure [Abstract]

Summary of the Quarterly Results of Operations

The following is a summary of the quarterly results of operations for the years ended December 31, 2020 and 2019:


	2020
	March 31		June 30		September 30		December 31

Research and development expenses	$	13,750	$	12,720	$	18,841	$	17,473
General and administrative expenses	4,998		6,289		6,643		8,022
Loss from operations	(18,748)		(19,009)		(25,484)		(25,495)
Net income (loss) attributable to common stockholders	$	(15,076)	$	(18,589)	$	(25,450)	$	(25,432)
Basic earnings (loss) per common share	$	(0.28)	$	(0.32)	$	(0.27)	$	(0.27)
Diluted earnings (loss) per common share	$	(0.28)	$	(0.32)	$	(0.27)	$	(0.27)


	2019
	March 31		June 30		September 30		December 31

Research and development expenses	$	7,685	$	10,009	$	10,383	$	11,567
General and administrative expenses	5,481		5,198		4,674		6,275
Income (loss) from operations	(13,166)		(15,207)		(15,057)		(17,842)
Net income (loss) attributable to common stockholders	$	(12,501)	$	(14,443)	$	(14,437)	$	(17,478)
Basic earnings (loss) per common share	$	(0.30)	$	(0.35)	$	(0.35)	$	(0.39)
Diluted earnings (loss) per common share	$	(0.30)	$	(0.35)	$	(0.35)	$	(0.39)

Summary of Significant Accounting Policies - Segment and Geographic Information (Details)	12 Months Ended
	Dec. 31, 2020 segment
Accounting Policies [Abstract]
Number of operating segments	1
Number of reporting segments	1

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) $ in Millions	Dec. 31, 2020 USD ($)
Accounting Policies [Abstract]
Cash, cash equivalents and available for sale securities	$ 210.0

Summary of Significant Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2020
Minimum
Property and equipment
Estimated useful lives	3 years
Maximum
Property and equipment
Estimated useful lives	10 years

Summary of Significant Accounting Policies - Share-Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Apr. 30, 2016
Share-Based Compensation
Expected dividend yield	0.00%
Share-based compensation expense	$ 8,323	$ 9,180	$ 11,072
Research and development
Share-Based Compensation
Share-based compensation expense	4,166	4,260	4,967
General and administrative
Share-Based Compensation
Share-based compensation expense	4,157	4,920	$ 6,105
ESPP
Share-Based Compensation
Share-based compensation expense	$ 100	$ 100
ESPP \| Maximum
Share-Based Compensation
Number of shares reserved for issuance under the Plan (in shares)				1,000,000

Summary of Significant Accounting Policies - Schedule of Weighted-Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	0.22%	1.38%	2.39%
Risk-free interest rate, maximum	1.34%	2.54%	2.95%
Expected dividend yield	0.00%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected common stock price volatility	118.00%	110.00%	85.00%
Expected term of options (years)	4 years 7 months 6 days	4 years 9 months 18 days	6 years
Expected dividend yield	0.00%	0.00%	0.00%

Common Stock - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		12 Months Ended
	Dec. 06, 2019	Jul. 22, 2019	Jun. 30, 2020	Jul. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Number of warrants issued (in shares)			1,914,280
Payments of stock issuance costs	$ 3,000		$ 10,100
Proceeds from issuance of common stock and pre-funded warrants, net, and related to acquisition			$ 150,100
Payment of other stock issuance costs	400
Sale of stock, consideration received on transaction	$ 42,600
License Agreements \| University Of Massachusetts (UMass) \| miniCEP290
Class of Stock [Line Items]
Shares issued for license fees (in shares)		75,000		75,000
Shares issued for license agreement (in shares)		100,000
Underwritten Offering
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)			28,503,220
Sale of stock, price per share (in dollars per share)			$ 4.10
Underwritten Offering, Underwriters
Class of Stock [Line Items]
Sale of stock, price per share (in dollars per share)			$ 3.854
Private Placement
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)			8,649,453
Warrant price (USD per share)			$ 4.099
Proceeds from issuance of common stock and pre-funded warrants, net, and related to acquisition					$ 33,237	$ 0	$ 0
Private Placement, Underwriters
Class of Stock [Line Items]
Warrant price (USD per share)			$ 3.853
Public Stock Offering
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	6,250,000
Sale of stock, price per share (in dollars per share)	$ 4.00
Number of warrants issued (in shares)	3,750,000
Warrant price (USD per share)	$ 3.999
Proceeds from issuance of common stock and pre-funded warrants, net, and related to acquisition					$ 116,883	$ 42,565	$ 0
Over-Allotment Option
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	1,500,000
Sale of stock, price per share (in dollars per share)	$ 3.736
Warrant price (USD per share)	$ 3.735

Net Income (Loss) Per Common Share - Narrative (Details) - shares	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Pre-funded warrants outstanding (in shares)	3,164,280	3,750,000

Net Income (Loss) Per Common Share - Schedule of Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Basic and diluted net loss per common share calculation:
Net income (loss)									$ (84,547)	$ (58,859)	$ 63,087
Weighted average common shares outstanding - basic (in shares)									74,185	42,224	37,061
Plus: net effect of dilutive stock options and unvested restricted stock units (in shares)									0	0	27
Weighted average common shares outstanding - dilutive (in shares)									74,185	42,224	37,088
Net income (loss) per common share - basic (USD per share)	$ (0.27)	$ (0.27)	$ (0.32)	$ (0.28)	$ (0.39)	$ (0.35)	$ (0.35)	$ (0.30)	$ (1.14)	$ (1.39)	$ 1.70
Net income (loss) per common share - diluted (USD per share)	$ (0.27)	$ (0.27)	$ (0.32)	$ (0.28)	$ (0.39)	$ (0.35)	$ (0.35)	$ (0.30)	$ (1.14)	$ (1.39)	$ 1.70

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Net Income (Loss) Per Common Share - Schedule of Potentially Dilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	10,886	8,261	6,474
Stock options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	8,928	6,780	5,873
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	1,958	1,481	601

Cash, Cash Equivalents and Available for Sale Securities - Narrative (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 66,373,000	$ 125,699,000
Cash	8,400,000	3,200,000
Cash equivalents	58,000,000.0	122,500,000
Available for sale debt securities	$ 143,674,000	$ 0

Cash, Cash Equivalents and Available for Sale Securities - Schedule of Available for Sale Securities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 143,671,000
Gross Unrealized Gains	13,000
Gross Unrealized Losses	(10,000)
Fair Value	143,674,000	$ 0
U.S. Treasury securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	54,225,000
Gross Unrealized Gains	8,000
Gross Unrealized Losses	0
Fair Value	54,233,000
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	79,282,000
Gross Unrealized Gains	4,000
Gross Unrealized Losses	(10,000)
Fair Value	79,276,000
Asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	10,164,000
Gross Unrealized Gains	1,000
Gross Unrealized Losses	0
Fair Value	$ 10,165,000

Cash, Cash Equivalents and Available for Sale Securities - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) for Unrealized Loss on Available for Sale Securities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	$ 117,203	$ 123,959	$ 38,041
Other comprehensive income	3	0	0
Ending balance	191,563	117,203	123,959
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	0	0
Current period changes in fair value before reclassifications, net of tax	3	0
Amounts reclassified from accumulated other comprehensive income, net of tax	0	0
Other comprehensive income	3	0
Ending balance	$ 3	$ 0	$ 0

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Fair Value Measurements
Transfer of assets from Level 1 to Level 2 of the fair value measurement hierarchy	$ 0	$ 0
Recurring basis \| Quoted prices in active markets for identical assets (Level 1) \| Money market funds
Fair Value Measurements
Investments in money market funds	58,042,000	108,585,000
Recurring basis \| Quoted prices in active markets for identical assets (Level 1) \| U.S. Treasury securities
Fair Value Measurements
Investments in money market funds	54,233,000
Recurring basis \| Quoted prices in active markets for identical assets (Level 1) \| Corporate debt securities
Fair Value Measurements
Investments in money market funds	0	0
Recurring basis \| Quoted prices in active markets for identical assets (Level 1) \| Asset-backed securities
Fair Value Measurements
Investments in money market funds	0
Recurring basis \| Significant other observable inputs (Level 2) \| Money market funds
Fair Value Measurements
Investments in money market funds	0	0
Recurring basis \| Significant other observable inputs (Level 2) \| U.S. Treasury securities
Fair Value Measurements
Investments in money market funds	0
Recurring basis \| Significant other observable inputs (Level 2) \| Corporate debt securities
Fair Value Measurements
Investments in money market funds	79,275,000	13,875,000
Recurring basis \| Significant other observable inputs (Level 2) \| Asset-backed securities
Fair Value Measurements
Investments in money market funds	10,166,000
Recurring basis \| Significant unobservable inputs (Level 3) \| Money market funds
Fair Value Measurements
Investments in money market funds	0	0
Recurring basis \| Significant unobservable inputs (Level 3) \| U.S. Treasury securities
Fair Value Measurements
Investments in money market funds	0
Recurring basis \| Significant unobservable inputs (Level 3) \| Corporate debt securities
Fair Value Measurements
Investments in money market funds	0	$ 0
Recurring basis \| Significant unobservable inputs (Level 3) \| Asset-backed securities
Fair Value Measurements
Investments in money market funds	$ 0

Inception 4 Acquisition (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		1 Months Ended	12 Months Ended
	Oct. 30, 2018	Oct. 31, 2018	Dec. 31, 2018
Schedule Of Asset Acquisition [Line Items]
Share price (USD per share)		$ 2.26
Non-cash charge on acquired in-process research and development			$ 6.9
Transaction costs			$ 1.3
Inception 4
Schedule Of Asset Acquisition [Line Items]
Number of shares issued in asset acquisition (in shares)		5.2
Value of shares issued in asset acquisition		$ 11.7
Contingent consideration	$ 105.0	$ 105.0
Contingently issuable shares, asset acquisition (in shares)	7.2	7.2
Contingently issuable shares, asset acquisition, as a percentage of total shares outstanding	19.90%	19.90%
Cash acquired in asset acquisition		$ 6.1
GA \| Inception 4
Schedule Of Asset Acquisition [Line Items]
Clinical and marketing approval milestones		45.0
Wet AMD \| Inception 4
Schedule Of Asset Acquisition [Line Items]
Clinical and marketing approval milestones		$ 60.0

Licensing and Commercialization Agreement (Details) $ in Thousands		1 Months Ended							8 Months Ended	12 Months Ended	110 Months Ended
	Jul. 22, 2019 shares	Oct. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Jul. 31, 2019 USD ($) shares	May 31, 2019 USD ($) licensedProduct shares	Jun. 30, 2018 USD ($)	Sep. 30, 2011 USD ($) shares	Oct. 31, 2020 milestone_payment_number	Dec. 31, 2020	Oct. 31, 2020 USD ($)	Dec. 31, 2018 USD ($)
Agreement
Number of licensed products \| licensedProduct						1
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF)
Agreement
Licensing agreement term							10 years
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product
Agreement
Amount to be paid on achievement of milestone												$ 23,500
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Commercial Sales Milestones Related to a Licensed Product
Agreement
Amount to be paid on achievement of milestone												$ 70,000
BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn)
Agreement
Licensing agreement term						10 years
Research and development \| RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF)
Agreement
Payments for license fees							$ 500
Research and development \| RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product
Agreement
Payments for license fees							23,500
Research and development \| RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Commercial Sales Milestones Related to a Licensed Product
Agreement
Payments for license fees							70,000
Research and development \| BEST1 License Agreement \| University Of Pennsylvania \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product \| Primary Licensed Product
Agreement
Payments for license fees						$ 200
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product \| Primary Licensed Product
Agreement
Payments for license fees						15,700
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product \| Other Licensed Product
Agreement
Payments for license fees						3,100
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Specified Commercial Sales Milestones Related to a Licensed Product \| Primary Licensed Product
Agreement
Payments for license fees						48,000
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Specified Commercial Sales Milestones Related to a Licensed Product \| Other Licensed Product
Agreement
Payments for license fees						9,600
General and administrative \| RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF)
Agreement
Payments for license fees							$ 30
General and administrative \| BEST1 License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product \| Primary Licensed Product
Agreement
Payments for license fees						18
License Agreements \| Archemix \| C5 Licensed Product
Agreement
Licensing agreement term								12 years
License Agreements \| Archemix \| Achievement of specified clinical and regulatory milestones \| C5 Licensed Product
Agreement
Payments for license fees		$ 6,000	$ 1,000					$ 1,000			$ 9,000
Number of milestone payments \| milestone_payment_number									2
Trial data period										12 months
License Agreements \| Archemix \| First indication \| C5 Licensed Product
Agreement
Amount to be paid on achievement of milestone								24,500
License Agreements \| Archemix \| Second and third indication \| C5 Licensed Product
Agreement
Amount to be paid on achievement of milestone								23,500
License Agreements \| Archemix \| Sustained delivery applications \| C5 Licensed Product
Agreement
Amount to be paid on achievement of milestone								$ 2,500
License Agreements \| University Of Massachusetts (UMass) \| miniCEP290
Agreement
Shares issued for license fees (in shares) \| shares	75,000				75,000
Licensing agreement term					10 years
License Agreements \| Research and development \| University Of Massachusetts (UMass) \| miniCEP290
Agreement
Payments for license fees				$ 400
License Agreements \| Research and development \| University Of Massachusetts (UMass) \| Achievement of specified clinical and regulatory milestones \| miniCEP290
Agreement
Payments for license fees					$ 14,750	$ 14,750
Shares issued for license fees (in shares) \| shares					75,000	75,000
License Agreements \| Research and development \| University Of Massachusetts (UMass) \| Specified Commercial Sales Milestones Related to a Licensed Product \| miniCEP290
Agreement
Payments for license fees					$ 48,000	$ 48,000
License Agreements \| General and administrative \| University Of Massachusetts (UMass) \| miniCEP290
Agreement
Payments for license fees				$ 18
License Agreements \| Series A Preferred Stock \| Archemix \| Achievement of specified clinical and regulatory milestones \| C5 Licensed Product
Agreement
Shares issued for license fees (in shares) \| shares								2,000,000
License Agreements \| Series B Preferred Stock \| Archemix \| Achievement of specified clinical and regulatory milestones \| C5 Licensed Product
Agreement
Shares issued for license fees (in shares) \| shares								500,000
Maximum \| License Agreements \| Archemix \| Achievement of specified clinical and regulatory milestones \| C5 Licensed Product
Agreement
Amount to be paid on achievement of milestone								$ 50,500
Maximum \| License Agreements \| Archemix \| First indication \| C5 Licensed Product
Agreement
Amount to be paid on achievement of milestone								24,500
Maximum \| License Agreements \| Archemix \| Second and third indication \| C5 Licensed Product
Agreement
Amount to be paid on achievement of milestone								23,500
Maximum \| License Agreements \| Archemix \| Sustained delivery applications \| C5 Licensed Product
Agreement
Amount to be paid on achievement of milestone								2,500
Maximum \| License Agreements \| Archemix \| Achievement of specified commercial milestones \| C5 Licensed Product
Agreement
Amount to be paid on achievement of milestone								$ 22,500

Financing Agreement with Novo Holdings A/S (Details)	1 Months Ended			12 Months Ended			19 Months Ended
Financing Agreement with Novo Holdings A/S (Details)	Nov. 30, 2014 USD ($)	Jan. 31, 2014 USD ($)	May 31, 2013 USD ($) tranche	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Nov. 30, 2014 USD ($)
Agreement
Gain on extinguishment of Royalty Purchase Liability				$ 0	$ 0	$ 125,000,000
Novo A/S \| Novo Agreement \| Fovista, Fovista-Related Products, and Other Products
Agreement
Number of tranches in financing \| tranche			3
Aggregate royalty rights			$ 125,000,000.0
Proceeds from royalty purchase agreement	$ 41,700,000	$ 41,700,000	41,700,000				$ 125,000,000.0
Royalty purchase liability			$ 125,000,000.0

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property and Equipment
Property and equipment, gross	$ 980	$ 980
Accumulated depreciation	(954)	(807)
Property and equipment, net	26	173
Depreciation expense	$ 143	162	$ 183
Minimum
Property and Equipment
Useful life	3 years
Maximum
Property and Equipment
Useful life	10 years
Manufacturing and clinical equipment
Property and Equipment
Property and equipment, gross	$ 47	47
Manufacturing and clinical equipment \| Minimum
Property and Equipment
Useful life	7 years
Manufacturing and clinical equipment \| Maximum
Property and Equipment
Useful life	10 years
Computer, software and other office equipment
Property and Equipment
Useful life	5 years
Property and equipment, gross	$ 933	$ 933

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Percent of pre-tax income:
U.S. federal statutory income tax rate	21.00%	21.00%	21.00%
State taxes, net of federal benefit	14.80%	10.90%	18.50%
Permanent items	0.20%	(1.00%)	4.00%
Impact of state rate changes	0.10%	0.10%	(0.20%)
Research and development credit	3.10%	2.80%	(2.40%)
Change in valuation allowance	(34.80%)	(33.60%)	(42.60%)
Effective income tax rate	4.40%	0.20%	(1.70%)

Income Taxes - Schedule of Components of Income Tax (Benefit) Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current:
Federal	$ 0	$ 0	$ 0
State	(3,695)	(111)	(1,063)
Deferred:
Federal	0	0	0
State	0	0	0
Income tax benefit	$ (3,695)	$ (111)	$ (1,063)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes - Schedule of Significant Components of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets (liabilities)
License and technology payments	$ 7,479	$ 7,116
Share-based compensation	23,266	22,131
Accrued expenses	427	362
Right-of-use asset	(40)	(163)
Lease obligation	38	162
Depreciation	6	(18)
Federal and state net operating loss carryforwards	130,524	105,375
Research and development credits	9,959	7,353
Other	7	6
Deferred income tax assets	171,666	142,324
Valuation allowance	(171,666)	(142,324)
Net deferred tax assets	$ 0
Net deferred tax assets		$ 0

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Income tax benefit		$ 3,695	$ 111	$ 1,063
Income tax receivable		1,765	882
Settlement of state franchise tax audit		5,200
Increase in deferred tax assets and corresponding valuation allowance		300
CARES Act
Operating Loss Carryforwards [Line Items]
Income tax receivable		1,800
Proceeds from income tax refunds			$ 1,800
CARES Act \| Forecast
Operating Loss Carryforwards [Line Items]
Proceeds from income tax refunds	$ 1,800
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Federal net operating loss carryforwards		$ 445,000

Income Taxes - Schedule of Position with Respect to Uncertain Tax Positions (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Opening balance	$ 12,227
Gross amount of increases in unrecognized tax benefits during the period - current year provisions	0
Gross amount of increases in unrecognized tax benefits during the period - prior year provisions	0
Gross amount of decreases in unrecognized tax benefits during the period - other	(659)
Decreases due to settlement with tax authorities during the period	(4,845)
Reduction of unrecognized tax benefits due to expiration of the state of limitations during the period	0
Closing Balance	$ 6,723

Operating Leases - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Operating lease right-of-use asset	$ 120	$ 496
Operating lease liability	115
Operating lease rent expense	600	1,000
Operating lease rent expense			$ 800
Cash paid from operating cash flows	$ 600	$ 1,000
Operating lease, weighted average remaining lease term	2 years 1 month 6 days
Weighted average estimated incremental borrowing rate	3.40%

Operating Leases - Schedule of Operating Lease Liability Maturities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Future minimum rental commitments under non-cancelable operating leases
2021	$ 57
2022	58
2023	5
Total minimum lease payments	120
Less imputed interest	(5)
Present value of minimum lease payments	115
Less current portion	54	$ 495
Total long-term operating lease liabilities	$ 61	$ 0

Commitments and Contingencies - Narrative (Details) - USD ($) $ in Thousands			1 Months Ended									110 Months Ended
	Jul. 22, 2019	Oct. 30, 2018	Oct. 31, 2020	Mar. 31, 2020	Sep. 30, 2019	Jul. 31, 2019	May 31, 2019	Apr. 30, 2019	Oct. 31, 2018	Jun. 30, 2018	Sep. 30, 2011	Oct. 31, 2020	Dec. 31, 2018
Cano v. Guyer, et al., No. 650601/2018
Commitments and contingencies
Litigation settlement awared to other party								$ 300
License Agreements \| Archemix \| C5 Licensed Product \| Achievement of specified clinical and regulatory milestones
Commitments and contingencies
Payments for license fees			$ 6,000	$ 1,000							$ 1,000	$ 9,000
License Agreements \| Archemix \| C5 Licensed Product \| Achievement of specified clinical and regulatory milestones \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone											50,500
License Agreements \| Archemix \| C5 Licensed Product \| First indication
Commitments and contingencies
Amount to be paid on achievement of milestone											24,500
License Agreements \| Archemix \| C5 Licensed Product \| First indication \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone											24,500
License Agreements \| Archemix \| C5 Licensed Product \| Second and third indication
Commitments and contingencies
Amount to be paid on achievement of milestone											23,500
License Agreements \| Archemix \| C5 Licensed Product \| Second and third indication \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone											23,500
License Agreements \| Archemix \| C5 Licensed Product \| Sustained delivery applications
Commitments and contingencies
Amount to be paid on achievement of milestone											2,500
License Agreements \| Archemix \| C5 Licensed Product \| Sustained delivery applications \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone											2,500
License Agreements \| Archemix \| C5 Licensed Product \| Achievement of specified commercial milestones \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone											$ 22,500
License Agreements \| University Of Massachusetts (UMass) \| miniCEP290
Commitments and contingencies
Shares issued for license fees (in shares)	75,000					75,000
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product
Commitments and contingencies
Amount to be paid on achievement of milestone													$ 23,500
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Commercial Sales Milestones Related to a Licensed Product
Commitments and contingencies
Amount to be paid on achievement of milestone													$ 70,000
Inception 4
Commitments and contingencies
Contingent consideration		$ 105,000							$ 105,000
Contingently issuable shares, asset acquisition (in shares)		7,200,000							7,200,000
Contingently issuable shares, asset acquisition, as a percentage of total shares outstanding		19.90%							19.90%
Inception 4 \| GA
Commitments and contingencies
Clinical and marketing approval milestones									$ 45,000
Inception 4 \| Wet AMD
Commitments and contingencies
Clinical and marketing approval milestones									$ 60,000
Research and development \| License Agreements \| University Of Massachusetts (UMass) \| miniCEP290
Commitments and contingencies
Payments for license fees					$ 400
Research and development \| License Agreements \| University Of Massachusetts (UMass) \| miniCEP290 \| Achievement of specified clinical and regulatory milestones
Commitments and contingencies
Payments for license fees						$ 14,750	$ 14,750
Shares issued for license fees (in shares)						75,000	75,000
Research and development \| License Agreements \| University Of Massachusetts (UMass) \| miniCEP290 \| Specified Commercial Sales Milestones Related to a Licensed Product
Commitments and contingencies
Payments for license fees						$ 48,000	$ 48,000
Research and development \| RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF)
Commitments and contingencies
Payments for license fees										$ 500
Research and development \| RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product
Commitments and contingencies
Payments for license fees										23,500
Research and development \| RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Commercial Sales Milestones Related to a Licensed Product
Commitments and contingencies
Payments for license fees										$ 70,000
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Primary Licensed Product \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product
Commitments and contingencies
Payments for license fees							15,700
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Primary Licensed Product \| Specified Commercial Sales Milestones Related to a Licensed Product
Commitments and contingencies
Payments for license fees							48,000
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Other Licensed Product \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product
Commitments and contingencies
Payments for license fees							3,100
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Other Licensed Product \| Specified Commercial Sales Milestones Related to a Licensed Product
Commitments and contingencies
Payments for license fees							$ 9,600

Stock-Based Compensation and Compensation Plans - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended
	Feb. 28, 2021	Mar. 31, 2020	Apr. 30, 2016	Aug. 31, 2013	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Oct. 31, 2019
Stock Option and Compensation Plans
Options outstanding (in shares)						8,526,000
Weighted-average exercise price of options (in dollars per share)						$ 9.42
Weighted-average remaining contractual life of options						7 years 7 months 6 days
Options, vested and expected to vest, outstanding, aggregate intrinsic value						$ 20,600
Share-based compensation expense						$ 8,323	$ 9,180	$ 11,072
Shares issued under ESPP (in shares)							70,466
ESPP
Stock Option and Compensation Plans
Number of shares of common stock available for issuance under the Plan (in shares)						805,361
Purchase price of common stock as percentage of fair market value			85.00%
Share-based compensation expense						$ 100	$ 100
Expected weighted average period to recognize share-based compensation costs						2 months 12 days
Common stock issued (in shares)						76,402
Proceeds from stock plans						$ 147
Restricted stock units
Stock Option and Compensation Plans
Share-based compensation expense							0
RSUs expected to vest (in shares)						1,725,000
Weighted-average fair value of RSUs expected to vest (in dollars per share)						$ 5.25
Aggregate intrinsic value of RSUs expected to vest						$ 11,900
Total fair value vested						4,600
Employees \| Stock options
Stock Option and Compensation Plans
Share-based compensation expense						4,700	5,900	7,600
Unrecognized share-based compensation costs for option awards, net of estimated forfeitures						$ 8,600
Expected weighted average period to recognize share-based compensation costs						5 years 9 months 18 days
Employees \| Restricted stock units
Stock Option and Compensation Plans
Share-based compensation expense						$ 3,300	3,000	3,300
Expected weighted average period to recognize share-based compensation costs						2 years
Unrecognized compensation costs, net of estimated forfeitures						$ 14,400
Consultants \| Non-employee Options
Stock Option and Compensation Plans
Share-based compensation expense						200	$ 300	$ 200
Unrecognized share-based compensation costs for option awards, net of estimated forfeitures						$ 100
Expected weighted average period to recognize share-based compensation costs						2 years 4 months 24 days
Consultants \| Restricted stock units
Stock Option and Compensation Plans
Expected weighted average period to recognize share-based compensation costs						2 years 10 months 24 days
Unrecognized compensation costs, net of estimated forfeitures						$ 100
Maximum \| ESPP
Stock Option and Compensation Plans
Number of shares reserved for issuance under the Plan (in shares)			1,000,000
2013 Plan
Stock Option and Compensation Plans
Number of shares of common stock available for issuance under the Plan (in shares)						421,000
Annual increase in shares reserved for issuance under the Plan (in shares)				2,542,372
Annual increase in shares reserved for issuance under the Plan (as a percent)				4.00%
Increase in number of shares available under the Plan (in shares)						13,081,000
2013 Plan \| Subsequent Event
Stock Option and Compensation Plans
Increase in number of shares available under the Plan (in shares)					2,542,000
2013 Plan \| Maximum
Stock Option and Compensation Plans
Number of shares reserved for issuance under the Plan (in shares)				3,359,641
2007 Plan
Stock Option and Compensation Plans
Number of shares of common stock available for issuance under the Plan (in shares)				739,317
2019 Inducement Plan \| Stock options
Stock Option and Compensation Plans
Number of shares reserved for issuance under the Plan (in shares)									1,000,000
Number of shares of common stock available for issuance under the Plan (in shares)						555,000
Increase in number of shares available under the Plan (in shares)		1,000,000
2019 Inducement Plan \| Stock options \| Subsequent Event
Stock Option and Compensation Plans
Increase in number of shares available under the Plan (in shares)	600,000

Stock-Based Compensation and Compensation Plans - Summary of Stock Option Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Common Stock Options
Outstanding at beginning of year (in shares)	6,780	5,903	5,284
Granted (in shares)	2,630	1,610	1,293
Exercised (in shares)	(109)	(80)	0
Expired or forfeited (in shares)	(373)	(653)	(674)
Outstanding at end of year (in shares)	8,928	6,780	5,903
Weighted Average Exercise Price
Outstanding at beginning of year (in dollars per share)	$ 10.89	$ 13.72	$ 19.58
Granted (in dollars per share)	6.10	4.26	1.67
Exercised (in dollars per share)	2.89	2.66	0
Expired or forfeited (in dollars per share)	19.49	21.16	36.54
Outstanding at end of year (in dollars per share)	$ 9.22	$ 10.89	$ 13.72
Options exercisable at end of year (in shares)	4,462	3,317	2,709
Weighted average grant date fair value (per share) of options granted during the period (in dollars per share)	$ 13.51	$ 3.37	$ 1.20

Stock-Based Compensation and Compensation Plans - Options Outstanding and Exercisable by Exercise Price and Options Exercised (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($) $ / shares shares
Options Outstanding
Total Options Outstanding (in shares) \| shares	8,928
Weighted Average Remaining Life (Years)	7 years 7 months 6 days
Weighted Average Exercise Price (in dollars per share)	$ 9.22
Aggregate Intrinsic Value of Options Outstanding \| $	$ 20,553
Options Exercisable
Number Exercisable (in shares) \| shares	4,462
Weighted Average Exercise Price (in dollars per share)	$ 13.51
Aggregate Intrinsic Value of Options Exercisable \| $	$ 11,741
$1.13-$2.90
Range of Exercise Prices
Exercise prices, low end of range (in dollars per share)	$ 1.13
Exercise prices, high end of range (in dollars per share)	$ 2.90
Options Outstanding
Total Options Outstanding (in shares) \| shares	1,352
Weighted Average Remaining Life (Years)	7 years 8 months 12 days
Weighted Average Exercise Price (in dollars per share)	$ 1.68
Options Exercisable
Number Exercisable (in shares) \| shares	808
Weighted Average Exercise Price (in dollars per share)	$ 1.79
$2.91-$3.18
Range of Exercise Prices
Exercise prices, low end of range (in dollars per share)	2.91
Exercise prices, high end of range (in dollars per share)	$ 3.18
Options Outstanding
Total Options Outstanding (in shares) \| shares	2,053
Weighted Average Remaining Life (Years)	7 years 6 months
Weighted Average Exercise Price (in dollars per share)	$ 2.99
Options Exercisable
Number Exercisable (in shares) \| shares	1,180
Weighted Average Exercise Price (in dollars per share)	$ 2.94
$3.19-$4.88
Range of Exercise Prices
Exercise prices, low end of range (in dollars per share)	3.19
Exercise prices, high end of range (in dollars per share)	$ 4.88
Options Outstanding
Total Options Outstanding (in shares) \| shares	1,790
Weighted Average Remaining Life (Years)	7 years 8 months 12 days
Weighted Average Exercise Price (in dollars per share)	$ 4.24
Options Exercisable
Number Exercisable (in shares) \| shares	1,022
Weighted Average Exercise Price (in dollars per share)	$ 4.39
$4.89-$8.77
Range of Exercise Prices
Exercise prices, low end of range (in dollars per share)	4.89
Exercise prices, high end of range (in dollars per share)	$ 8.77
Options Outstanding
Total Options Outstanding (in shares) \| shares	2,491
Weighted Average Remaining Life (Years)	9 years 7 months 6 days
Weighted Average Exercise Price (in dollars per share)	$ 6.64
Options Exercisable
Number Exercisable (in shares) \| shares	211
Weighted Average Exercise Price (in dollars per share)	$ 5.24
$8.78-$73.22
Range of Exercise Prices
Exercise prices, low end of range (in dollars per share)	8.78
Exercise prices, high end of range (in dollars per share)	$ 73.22
Options Outstanding
Total Options Outstanding (in shares) \| shares	1,242
Weighted Average Remaining Life (Years)	3 years 9 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 40.08
Options Exercisable
Number Exercisable (in shares) \| shares	1,241
Weighted Average Exercise Price (in dollars per share)	$ 40.08

Stock-Based Compensation and Compensation Plans - Schedule of Cash Proceeds From and Aggregate Intrinsic Value of Stock Options Exercised (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Cash proceeds from options exercised	$ 314	$ 192	$ 0
Aggregate intrinsic value of options exercised	$ 393	$ 135	$ 0

Stock-Based Compensation and Compensation Plans - Summary of Outstanding RSU Awards Granted (Details) - Restricted stock units shares in Thousands	12 Months Ended
	Dec. 31, 2020 $ / shares shares
Restricted Stock Units
Outstanding, beginning of period (in shares) \| shares	1,481
Awarded (in shares) \| shares	1,232
Vested (in shares) \| shares	(657)
Forfeited (in shares) \| shares	(98)
Outstanding, end of period (in shares) \| shares	1,958
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 7.79
Awarded (in dollars per share) \| $ / shares	6.06
Vested (in dollars per share) \| $ / shares	7.20
Forfeited (in dollars per share) \| $ / shares	6.74
Outstanding, end of period (in dollars per share) \| $ / shares	$ 6.95

Employee Benefit Plan (Details) - USD ($) $ in Millions	12 Months Ended
Employee Benefit Plan (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Retirement Benefits [Abstract]
Defined contribution plan, cost recognized	$ 0.3	$ 0.2	$ 0.2

Selected Quarterly Financial Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Research and development expenses	$ 17,473	$ 18,841	$ 12,720	$ 13,750	$ 11,567	$ 10,383	$ 10,009	$ 7,685	$ 62,784	$ 39,644	$ 41,737
General and administrative expenses	8,022	6,643	6,289	4,998	6,275	4,674	5,198	5,481	25,952	21,628	23,612
Income (loss) from operations	(25,495)	(25,484)	(19,009)	(18,748)	(17,842)	(15,057)	(15,207)	(13,166)	$ (88,736)	$ (61,272)	$ (65,349)
Net income (loss) attributable to common stockholders	$ (25,432)	$ (25,450)	$ (18,589)	$ (15,076)	$ (17,478)	$ (14,437)	$ (14,443)	$ (12,501)
Basic (in dollars per share)	$ (0.27)	$ (0.27)	$ (0.32)	$ (0.28)	$ (0.39)	$ (0.35)	$ (0.35)	$ (0.30)	$ (1.14)	$ (1.39)	$ 1.70
Dilutive (in dollars per share)	$ (0.27)	$ (0.27)	$ (0.32)	$ (0.28)	$ (0.39)	$ (0.35)	$ (0.35)	$ (0.30)	$ (1.14)	$ (1.39)	$ 1.70

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details